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1 Cohorts  
1.1 Overview 
Our discovery cohort is the UK Biobank (UKB). In our replication analyses (Supplementary 
Information 4), we test the credibility of the lead SNPs found in the discovery cohort. These 
replications—which we call our “replication phase”—are conducted as a meta-analysis of our 14 
replication cohorts and (for PROTEIN, CARBOHYDRATE AND FAT) previously published summary 
statistics from DietGen. 
For all other analyses, including polygenic prediction and bioannotation, we use the results from 
all cohorts meta-analyzed together: UKB, the 14 replication cohorts, and DietGen. We refer to 
these meta-analyses as our “combined meta-analyses”. Our study design is summarized with a 
flow chart (Extended Data Figure 2). 
An overview of all cohorts included in the combined meta-analysis is listed in Supplementary 
Table 1.1. A short overview of the dietary intake questionnaires, along with phenotypic 
summary statistics for cohort demographic variables and dietary intake estimates can be found in 
Supplementary Table 1.2. The cohort-specific exclusion criteria and genotyping and imputation 
filters can be found in Supplementary Table 1.3. 
1.2 Discovery phase 
Our discovery sample consists of individuals of European (white British, Scottish, Irish, or other 
European background) ancestry of the UKB. The UKB, which was established in 20061, is a 
large British general population cohort of individuals aged 45 to 69 years at recruitment. 
Individuals who were registered with the National Health Service and who lived in proximity to 
one of the 22 assessment centers were eligible for participation. In total, 9.2 million individuals 
received a mailed invitation, of whom N = 503,325 (response rate 5.4%) agreed to participate. 
All participants provided informed consent. When we were made aware of participants who 
withdrew consent, these participants were excluded from any new analyses. 
The dietary-intake questionnaire in UKB was administered once at a UKB assessment center by 
use of a touchscreen. However, only 14.1% of participants completed this questionnaire at the 
assessment center, as it was added to the questionnaire battery later during the recruitment 
process. In addition, four invitations for an online version were sent to N = 331,008 UKB 
participants with a known email address. Across these internet surveys, an average 31.4% 
responded and completed the full survey.  N = 150,617 completed at least one internet survey, 
which corresponds to 45.5% of individuals who were sent an invitation to participate. In total, 
40% of the UKB sample (N24HDR = 211,063 vs. Ntotal = 502,643) completed at least one dietary-
intake questionnaire. Of these N = 211,063 individuals, N = 175,253 passed internal quality 
control (both at the genotypic and phenotypic level; see Supplementary Table 3.3 for details) 
for GWAS.  
6 
 
1.3 Replication phase 
The 14 replication cohorts consist of numerous cohorts from the Netherlands (Lifelines2 and 
Rotterdam Study3), United Kingdom (ALSPAC4,5, Fenland6), and United States (Framingham 
Heart Study7, Health and Retirement Study8, Women’s Health Initiative9: GARNET, HIPFX, 
and WHIMS+), and from the international study consortium of EPIC-InterAct10, which 
encompasses cohorts from France, Germany, Italy, Spain and Sweden. All participants in these 
cohorts are adults who provided informed consent. Recruitment of replication cohorts was based 
on a priori power calculations for replication of the polygenic score and individual SNPs in 
holdout cohorts. Our initial aim was to continue recruitment until we achieved the minimum 
sample size needed to replicate each phenotype’s primary lead SNP with a one-sided alpha of 
5% with at least 80% power. With the delayed second release of the UKB, however, we kept the 
recruitment of the replication phase open for longer, and we surpassed our original goal of N ≥ 
141,000, which was needed to identify at least one locus at genome-wide significance with 80% 
power for each macronutrient (as detailed in our analysis plan https://osf.io/mt9kt/). In addition, 
we obtained access to the summary statistics from the CHARGE11 and DietGen12 consortia, 
which previously performed GWAS on percentage intake from protein, carbohydrate and fat. 
While this phenotype definition differs slightly from ours, we find large enough genetic 
correlations between DietGen and our replication phase, discovery phase, and combined 
replication and discovery phase to warrant meta-analysis (Supplementary Information 4.1). In 
the end, we decided to not include CHARGE in our replication phase, since the sample overlap 
between our replication cohorts and CHARGE cohorts turned out to be much larger than we 
expected.  
Since the DietGen summary statistics only included HapMap2 SNPs, we impute the DietGen 
results to 1000 Genomes Phase 3 Version 2 EUR (information from 381 European individuals) 
using impG13 software. In our quality control procedure for DietGen (Supplementary 
Information 3.3), we apply more stringent SNP filters compared to other cohorts of N > 10,000. 
We also obtained access to the ARIC cohort via dbGaP (https://dbgap.ncbi.nlm.nih.gov). This 
cohort was not included in our meta-analysis since allele-frequency plots (comparing allele 
frequencies in the ARIC data with those in our reference panel) revealed a pervasive strand 
alignment issue that most likely arose from imputation, with probable large downstream effects. 
2 Phenotype definition 
2.1 Overview 
In UKB and the 14 replication cohorts, we apply our novel, non-linear correction method for 
total reported energy intake. The DietGen summary statistics, however, were based on a 
correction (% of total energy intake) that assumes linear scaling between the macronutrients and 




We perform genome-wide association analyses for four dietary composition phenotypes, which 
together comprise our measure of diet composition: 
 
1. Relative protein intake (PROTEIN) 
2. Relative fat intake (FAT) 
3. Relative carbohydrate intake (CARBOHYDRATE) 
4. Relative sugar intake (SUGAR) 
As an auxiliary analysis in the UKB, we also perform GWAS for saturated fat: 
5. Relative saturated fat intake (SATURATED FAT) 
These macronutrientsa  are corrected for total energy intake (Supplementary Information 2.6). 
This is to correct for total energy intake—which is hard to measure reliably14,15, and which is 
mainly a function of body size and physical activity16–18 (for further discussion see 
Supplementary Information 2.7). We are interested in studying the genetic architecture and 
genetic correlations of the relative intake of macronutrients. For instance, fat is the most energy-
dense of all macronutrients, so fat intake may be associated with obesity only by way of its 
calorie count. However, if the association between fat and obesity remains after correction for 
total energy intake, this potentially implies that fat has health effects through other pathways – 
for instance through specific effects on atherosclerosis or endocrine signaling. We do not 
perform GWAS for alcohol (i.e., ethanol) intake even though it is another component of total 
energy intake, since it is a non-essential macronutrient with various complicated associations, 
and thus outside of the scope of this project. 
2.3 Sugar intake 
In all our GWAS cohorts (both discovery and replication), the total sugar intake variable used in 
phenotype construction is a subset of the total carbohydrate intake variable. Our definition of 
sugar intake constitutes intake from short-chain saccharides: mono- and disaccharides. The 
predominantly consumed monosaccharides are glucose, fructose, and galactose, and the 
predominantly consumed disaccharides are sucrose (“table sugar”; a disaccharide chain of 
glucose and fructose), and lactose (“milk sugar”; a disaccharide chain of glucose and galactose). 
Sugars naturally occur in fruits and dairy, are often added to food or drinks in the form of 
sucrose or fructose, and are sweet in taste. Non-sugar carbohydrates are longer chains of 
saccharides, known as oligo- and polysaccharides (e.g., starch and glycogen), which are less 
sweet in taste. Cellulose is also a polysaccharide but is an insoluble and non-digestible fiber, and 
therefore is a negligible component of energy intake.  
The GWAS of carbohydrates includes intake from all saccharides, while the GWAS of sugar 
includes intake from mono- and disaccharides only. As noted above, this category includes not 
 
 
a A macronutrient is a molecule that human organisms can derive energy from.  
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only added and refined sugar (found in for instance, sugar-sweetened beverages and candy), but 
also natural sugars, found mainly in fruit and dairy products.  
An exception to this definition of the sugar phenotype was made for the two EPIC-InterAct 
cohorts, which only analyze sugars consumed as a single dietary intake of honey, syrup, jams, or 
other non-artificial sweeteners19. Participating cohorts of the InterAct conducted a dietary survey 
at baseline independently of each other, with cohort-specific dietary instruments, food frequency 
questionnaires or diet history19,20. Validity of dietary instruments was assessed in each cohort 
against 24-hour recalls, food diaries, or both21. Dietary variables were standardized across these 
cohorts as part of the multi-country epidemiological study of European Prospective Investigation 
into Cancer and Nutrition (EPIC). Food groups were harmonized across EPIC’s participating 
cohorts and standardized by using EPIC-SOFT software, which managed country-specific 
descriptions such as meals, foods, ingredients, and cooking methods19. Consumption of refined 
sugars, one of the 39 food groups in the harmonized data, is used in the current analysis. In 
Supplementary Information 4.1.4, we report the genetic correlation between a meta-analysis of 
the two EPIC-InterAct cohorts and a meta-analysis of the remaining cohorts for SUGAR. 
2.4 Note on misreporting 
Misreporting of dietary intake is a well-known and pernicious problem in nutritional 
epidemiology. Misreporting is non-random, with overweight individuals tending to misreport 
relatively more kilocalories15. This BMI-correlated misreporting distorts correlations between 
self-reported estimates of total energy intake and weight gain22. This differential misreporting is 
said to give rise to the ‘fundamental flaw of obesity research’23. For this reason, some 
researchers have called for abandoning self-reported total energy intake altogether14, but at a 
minimum, correcting macronutrients for total consumed energy is considered crucial24. 
Correcting macronutrients for total reported energy is insufficient, however, when the extent of 
misreporting differs across macronutrients. However, it is difficult to estimate the extent of 
macronutrient-specific misreporting, as only protein intake has a valid and reliable biomarker 
(24-hour urinary nitrogen output)25. Measuring misreporting of the other macronutrients is 
possible when food intake of participants is monitored and scored externally, for instance in the 
setting of laboratory confinement26,27 or with video-monitoring28. At the food-item level, snack 
foods26,29 and foods that are considered unhealthy may be especially selectively underreported30. 
A meta-analysis of five US studies with biomarkers for total energy and protein intake found that 
higher BMI is correlated with under-reporting of total protein and energy intake, but with over-
reporting of protein density (% protein of total energy intake, “protein density”)31. This was also 
true in a Danish sample32. Hence, any associations between relative protein intake and BMI 
could be biased upward by this effect.  
However, there are two reasons why protein-intake overreporting need not upwardly bias 
associations with BMI. First, Ankarfeldt et al.33 analyzed the same Danish sample described 
above, and still found that both self-reported relative protein intake and an objective measure 
(i.e., urine-ascertained) of relative protein intake were associated with fat mass gain to a similar 
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extent. Hence, the association between self-reported protein intake and weight gain was not 
biased by over-reporting of relative protein intake. Using longitudinal data on macronutrient 
substitution (i.e., individual changes in macronutrient composition over time), they found that the 
effect of protein on weight gain was similar when protein was substituted over time for any other 
macronutrient (fat, carbohydrates, or alcohol). Hence, weight gain appeared to be driven by high 
protein intake, and not low carbohydrate or fat intake. This is the only study we could find that 
compared self-reported to objective protein intake in relation to weight gain or BMI. Second, the 
construction of relative protein intake (i.e., protein density) by these studies31–33 tends to leave a 
negative correlation with total energy intake, as we show in Supplementary Information 2.7. 
This could lead to a downward bias in associations between protein density and BMI, as 
individuals with a higher protein density tend to consume fewer calories in total. This downward 
bias could cancel out the upward-biasing effect of overreporting. Thus, while we believe that 
macronutrient-specific misreporting might be an issue, it is unknown how it may affect 
associations with BMI and its related predictors and outcomes. 
Some might argue that macronutrient-specific misreporting can be addressed by excluding 
individuals most likely to misreport total energy intake. The assumption here is that extreme 
underreporters of total energy are also more likely to overreport their protein intake. These 
individuals are also more likely to be overweight. Excluding these individuals should then leave 
a sample of plausible reporters. A common exclusion criterion is referred to as the Goldberg cut-
off34, which effectively excludes individuals with implausible physical activity levels. These 
physical activity levels are not reported by individuals but are implied by the ratio of the 
individual’s predicted basal metabolic rate to the individual’s total reported energy intake22. 
According to this approach, an individual should be excluded from all analyses when their 
implied physical activity level is extremely deviant (e.g., +/- 2 standard deviations removed from 
a population average). Thus, individuals with extremely high physical-activity levels are deemed 
probable over-reporters, while individuals at the other end are deemed probable under-reporters.  
However, we believe that excluding individuals based on extreme reports of energy intake is 
undesirable for several reasons. First, this Goldberg exclusion creates a selection bias, whereby 
overweight individuals are disproportionately more likely to be removed from the sample22,35, 
which can induce spurious associations. In the worst case, collider bias is introduced, where 
associations have the wrong direction of association. Second, the Goldberg exclusion does not 
take into account individual levels of physical activity and may thus erroneously exclude 
individuals who in reality are at the extreme ends of the physical activity level distribution. At 
the same time, it may erroneously retain individuals whose actual physical activity levels do 
differ from their implied physical activity levels, but whose implied physical activity levels still 
fall within the population confidence bounds.  
Hence, we do not believe that performing additional analyses that exclude individuals according 
to a Goldberg(-like) cutoff are useful in our case. However, some cohorts did exclude individuals 
with extremely high or extremely low self-reported total energy intake (Supplementary Table 
1.3), as a strategy to remove a small set of extreme outliers that might bias regression estimates. 
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2.5 Dietary intake in the UKB 
2.5.1 Short description 
The estimates of total macronutrient intakes we use were derived by UKB and expressed in 
grams. The energy values of the macronutrients are obtained using the conversion factor of 4 
kcal/gram for protein, sugar and carbohydrate, and 9 kcal/gram for fat. We use kilocalories for 
convenience, although units are irrelevant as long as they are consistent. Dietary intakes were 
obtained by UKB on the basis of responses from a computerized 24-hour dietary recall (24HDR) 
questionnaire called “Oxford WebQ”, which was designed using repeated testing to ensure 
comparability to interview-based measures36,37. The macronutrient and energy intakes were 
derived by UKB from the information recorded in McCance and Widdowson’s “The 
Composition of Food” and its supplements, fifth edition38, taking into account sex-specific 
portion sizes and other factors. An example of the Oxford WebQ can be found onlineb.  
In UKB, participants were successively presented with lists of food items designed to capture the 
eating habits of the British population and asked how many portions (if any) of each food item 
they ate in the previous day. Individuals were not allowed to proceed to the next list of food 
items if they had missing answers. The questionnaire contained over 200 food items. 
Dietary intakes derived from 24HDR questionnaires exhibit more random variation than those 
derived from, for instance, the widely used food-frequency questionnaire (FFQ), in which 
participants are asked to report their intakes for a typical day in the last week or month. This 
random variation can be averaged out as more 24HDR questionnaires are completed. However, 
dietary intakes from FFQs may be more strongly biased by systematic underreporting of total 
energy intake, and misreporting of foods that are considered unhealthy39,40. Researchers 
sometimes attempt to quantify these measurement errors by comparing intakes from repeated 
24HDR measurements to those from FFQs41. FFQs are used by all of our replication cohorts. 
2.5.2 Correction for weekend intake 
As noted earlier, a key difference between 24HDR- and FFQ-estimates of dietary intake is that 
the former method intends to measure intake during the previous day, while FFQ intends to 
measure habitual dietary intake (i.e., on a “typical” day). As such, 24HDR-data require a 
correction for day of the week that the assessment was performed for. In UKB, data for both 
weekend and weekdays are available: the first 24HDR assessment in UKB took place at the 
UKB assessment centers, which was open on Monday through Saturday (and on rare occasions 
on Sundays). The additional four email invitations were sent out on different days of the week in 
each cycle. 
It is important to note that not all UKB participants completed the questionnaire for both a 
weekday and a weekend-day, which hampers the implementation of a simple weighting of 
weekend days (i.e., 2/7 weight for weekend days and 5/7 weight for weekdays). This inability to 
account for weekend data is potentially problematic, as dietary intake differs in the weekend, 
 
 
b URL: http://www.ceu.ox.ac.uk/research/web-based-questionnaires. 
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with higher total energy and alcohol intake, and relatively higher protein and fat intake42,43. 
Hence, we may underestimate intakes for individuals who only have weekday reports.  
Our approach is to apply an empirical “day-of-the-week” weight to the total intakes of energy, 
fat, protein, carbohydrate, and sugar. We take into account that UKB asked participants to report 
on their dietary intake for the preceding day. We regress the total intakes on dummies for all 
weekend- and weekdays, excluding Wednesday, which thus serve as the “reference” category in 
each regression. We do this separately for each of the five intake estimates (i.e., total calories; 
protein; fat; carbohydrates; and sugar), and for each of the five measurement rounds, giving rise 
to 5×5 = 25 regressions. Here, we find that Fridays are empirical “weekend days” in terms of 
dietary intake, while Monday, Tuesday and Thursday are regular weekdays in the sense that they 
do not differ from Wednesday. Individuals tended to consume more total energy on Friday, 
Saturday and Sunday. They also tended to eat less carbohydrates and sugar, and more protein 
and fat on these weekend days. 
In each of these 25 regressions, we store the six regression coefficients (one for all days except 
our baseline day, Wednesday), and then compute the regression residuals. To illustrate, in the 
first measurement, the estimated coefficient of total energy intake on the day-of-the-week 
dummies is 359 for Saturday (i.e., ?̂?𝛽𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠). Hence, the average UKB participant consumed 
359 kilocalories more on Saturday than on Wednesday. If an individual reported dietary intake 
for a Saturday in that measurement round, 359 kilocalories would thus be subtracted from that 
person’s total estimated energy intake. Of note, we apply these regression-based corrections to 
each day of the week, and not just to the weekend days. After correcting the total intakes in each 
measurement round, we continue with our phenotype construction as usual: we compute the 
average corrected intakes across the five measurement rounds, and use these for the log-log 
regressions described in Supplementary Information 2.6. 
Supplementary Table 2.3 shows the differences between the average total intake estimates and 
the corrected average total intake estimates in genotyped individuals of European ancestry from 
the first release of the UKB. While the differences are small, all are statistically significant in 
paired t-tests. However, we did find that these weekday-corrected phenotypes correlated almost 
perfectly with the non-corrected phenotypes (ranging between r = 0.991 and r = 0.998), 
indicating that a correction for weekend is not strictly necessary, but still useful to increase 
measurement precision, and, therefore, statistical power. 
2.5.3 Test-retest reliability 
As noted earlier (Supplementary Information 2.5.1), UKB participants have up to five 24HDR 
measurements. Due to random fluctuation in day-to-day eating habits and episodic consumption 
of certain foods or nutrients (e.g., fish, dark green vegetables)44, imperfect correlation between 
measurement rounds is expected. Therefore, true “habitual” intake is usually envisioned as long-
term average intake44. Random measurement noise will bring a downward bias to estimated 
coefficients that cannot be alleviated with larger sample sizes. 
Among the number of individuals that are included in the GWAS with 24HDR data, N = 64,910 
have 1 observation; N = 40,926 have 2 observations; N = 37,214 have 3 observations; N = 27,023 
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have 4 observations; and N = 5,180 have 5 observations. The repeated observations allow us to 
calculate test-retest reliability estimates for the four macronutrients. We use Cronbach’s alpha 
(denoted with α) as a measure of consistency across measurements in time. We perform the log-
log regressions (Supplementary Information 2.6) on the weekend-corrected total macronutrient 
intakes (Supplementary Information 2.5.2) for each measurement cycle, and apply listwise 
deletion of observations. This means that we retained all information on all available 
measurements, as the majority of participants did not have the full set of five observations.  
The results are displayed in Supplementary Table2.2. Given the natural daily fluctuation in 
eating habits, we expect the macronutrient composition to not be perfectly stable across 
measurements. The lowest reliability is found for protein (α = 0.60) and the highest reliability for 
sugar (α = 0.79). Fat (α = 0.69) and carbohydrate (α = 0.76) are in the middle. The rank-order of 
reliability estimates corresponds to the rank-order of heritability estimates for the macronutrients, 
with relative protein intake being the least heritable, and relative sugar and carbohydrate intake 
being the most heritable (Supplementary Information 8). The results show that self-reported 
consumption of relative sugar and carbohydrate intake is especially stable, while relative fat and 
protein intake might be more subject to random day-to-day fluctuations or recalled with less 
accuracy. 
2.6 Phenotype definition 
Because we are interested in the identification of genetic variants associated with diet 
composition, we seek to correct the macronutrient intakes for reported total energy intake. A 
standard approach is to divide macronutrient intake by total energy intake, resulting in intake 
fractions which are often referred to as “macronutrient densities”18. However, if relative 
macronutrient intake does not scale linearly with total energy intake, the construction of simple 
macronutrient proportions may not represent the optimal correction for total energy intake. The 
macronutrient intakes would then not be properly corrected for total energy intake, leaving 
residual correlations between macronutrient- and total energy-intake, which potentially differs by 
macronutrient. This correlation could bias any downstream associations related to diet 
composition differentially for the macronutrients. Since total energy intake is mainly a function 
of body size and physical activity16–18, this can also bias associations with BMI and related health 
outcomes. Using a ratio as an outcome variable may induce spurious correlations between the 
ratio and the denominator. This is a well-known problem of crude ratios that was noted by 
Pearson over a century ago45. We alleviate this concern by correcting the denominator for an 
empirical “correction” factor, 𝛽𝛽, as detailed below. 
Keeping these concerns in mind, our own phenotype definition of the energy-corrected 
macronutrient intakes is given by 




which could be described as an “adjusted macronutrient density”. Here, the macronutrient- and 
total energy intake have to be measured in the same unit (e.g., kilocalories).  𝛽𝛽 is a correction 
factor that is estimated with the procedure described below. 
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The simple macronutrient density (i.e., percentage intake) implicitly assumes 𝛽𝛽 to be equal to 
one. However, it is possible to estimate the value of 𝛽𝛽 with a multiplicative regression model. 
We estimate 𝛽𝛽 separately for each macronutrient j, where the reported macronutrient intake (in 
kcal) is regressed on reported energy intake (in kcal). The estimation of 𝛽𝛽𝑗𝑗 is achieved by means 
of a log-log regression, which transforms the multiplicative model into a simple linear regression 
model. More specifically, the multiplicative model for individual i and macronutrient j is given 
by the generic form below: 
𝑒𝑒𝑖𝑖 =  𝛼𝛼𝑥𝑥𝑖𝑖𝛽𝛽𝑗𝑗𝜀𝜀𝑖𝑖 
where 𝑒𝑒𝑖𝑖 is the outcome, which we wish to correct for the effects of regressor 𝑥𝑥𝑖𝑖. We are 
interested in the residual 𝜀𝜀𝑖𝑖 of this model. Rearranging the terms, we have the following 




In our genome-wide association analyses, the phenotypes are constructed according to the left-
hand side of this equation, replacing 𝛽𝛽 by its regression estimate, resulting from a log-log 
regression. That is, we estimate 𝛽𝛽 by re-writing the multiplicative regression as a log-log 
regression, so it can be estimated using ordinary least squares (OLS): 
log (𝑒𝑒𝑖𝑖) = log(𝛼𝛼) + 𝛽𝛽𝑗𝑗log (𝑥𝑥𝑖𝑖) + log (𝜀𝜀𝑖𝑖) 
The coefficient 𝛽𝛽𝑗𝑗 represents the percentage change in 𝑒𝑒𝑖𝑖 that follows a one percent change in 𝑥𝑥𝑖𝑖. 
If this is smaller or larger than one, the relationship between 𝑥𝑥𝑖𝑖 and 𝑒𝑒𝑖𝑖 is non-linear.  
The log-log regression model is often used in economics, where the coefficient is known as an 
‘elasticity’. An elasticity is a unitless measure of the extent to which one variable changes in 
response to a change in another variable.  
The coefficient from the log-log regression is also sometimes referred to as the “attenuation” or 
“shrinkage” factor46. In health science, the log-log model underlies the construction of BMI – a 
measure of body weight corrected for body height (two variables that do not scale linearly). In 
the construction of BMI, body weight is corrected for squared body height (i.e., weight in 
kilograms, divided by height in meters squared). We confirm that a power of two constitutes the 
coefficient of a log-log regression of body weight (measured in kilograms) on body height 
(measured in meters) in the UKB (N = 444,648), with ?̂?𝛽 = 1.9995 (95% confidence interval = 
[1.991, 2.008]). Hence, dividing weight by height-squared represents the proper empirical 
correction factor for height in the UKB, providing an estimate of body density that proxies for 
body fat composition. 
All participating cohorts (with the exception of DietGen) estimate the coefficients from these 
log-log regressions and use the estimated coefficients to correct the total energy-intake term in 
the denominator. We report the coefficients obtained from those regressions for seven cohorts 
included in the meta-analysis (FHS, HRS, RSI/II/III, UKB, and WHI) in Supplementary Table 
2.3, and we plot the scatterplots and lines of fit for European individuals included in the first 
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release of the UKB in Extended Data Figure 1. Across the seven cohorts, we also report the 
point estimates, which were obtained with fixed-effects inverse-variance-weighted meta-
analysis, where the cohort weights were equal to 1/SE2.  
In six out of seven cohorts, the coefficient for fat intake is larger than one (all comparisons in 
this paragraph are statistically distinguishable from one at the 5% level). In one cohort (RSII), 
the coefficient was smaller than one. The meta-analysis point estimate was ?̂?𝛽 = 1.158 (95% CI 
[1.155, 1.161]). In all cohorts, the coefficient for protein intake is smaller than one, with a meta-
analysis point estimate ?̂?𝛽 = 0.817 (95% CI [0.814, 0.820]). The estimates for carbohydrate and 
sugar intake varied across cohorts. The meta-analyses imply coefficients smaller than one for 
both carbohydrate and sugar intake, with ?̂?𝛽 = 0.955 (95% CI [0.952, 0.958]) and ?̂?𝛽 = 0.921 (95% 
CI [0.916, 0.926]), for sugar and carbohydrate intake, respectively.  
Thus, we find that the reporting of relative macronutrient intake was not constant across different 
levels of total energy intake. The reported relative consumption of protein, sugar, and 
carbohydrates tend to decrease at higher levels of reported total energy intake. For fat intake, the 
reported relative consumption tends to increase at higher levels of reported total energy intake. 
Thus, according to the self-reports, compared to low energy diets, high energy diets consist of a 
higher ratio of fat to protein. 
2.7 Comparison to regular macronutrient densities 
In this section, we show that “regular” macronutrient densities (i.e., percentage intake of 
macronutrient with respect to total energy intake) tend to leave a residual correlation with total 
energy intake.  
Because high-energy diets tend to consist of relatively less protein and relatively more fat 
according to the self-reports (Supplementary Information 2.6), percentage protein intake is 
expected to have a negative correlation with total energy intake, while percentage fat intake is 
expected to have a positive correlation with total energy intake. These residual correlations have 
been described before, and have led to recommendations of regressing relative macronutrient 
intake on total energy intake, and using the residual from this analysis for further analyses24. 
(Since we observed non-linear correlations between macronutrient intake and total energy intake, 
we chose to use the back-transformed residual of a log-log regression as described in 
Supplementary Information 2.6) 
In Supplementary Table 2.4, we compare how our phenotypes (“adjusted macronutrient 
densities”) phenotypically correlate with total energy intake to how “regular macronutrient 
densities” phenotypically correlate with total energy intake. We study these correlations in four 
different cohorts: FHS, HRS, WHI, and UKB. We find sizeable correlations between total 
energy intake and percentage macronutrient intake, especially for protein intake (range: r = [-
0.284 (UKB), -0.055 (WHI)]) and fat intake (range: r = [0.065 (HRS), 0.223 (WHI)]), where the 
correlations are always statistically distinguishable from zero with P < 0.001. As expected, the 
stronger a macronutrient deviated from a linear relationship with total energy (i.e., the deviation 
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of the betas from 1 as reported in Supplementary Table 2.4), the stronger the correlation with 
total energy intake.  
In some cohorts, we also find correlations between our phenotypes and total energy intake that 
are statistically distinguishable from zero, but these are always smaller than r < 0.05. We believe 
these small correlation estimates are noise induced by the back-transformation of the regression 
residual, which is on a log scale as described in Supplementary Information 2.6. We conclude 
that our measure of macronutrient density is preferred to the regular measure of macronutrient 
density. 
2.8 Interpretation 
Studying energy-adjusted macronutrient intakes instead of total nutrient intakes has been called 
the “primary focus of nutritional epidemiology”24. Researchers generally do not study total 
unadjusted nutrient intakes because they are mainly a function of body size and physical activity, 
with taller, larger, and more physically active individuals requiring higher energy consumption to 
maintain their metabolic equilibrium17,18,24. Hence, associations between total nutrient intakes 
and health outcomes are uninformative47, especially if these health outcomes are related to body 
size and physical activity. In addition, total energy intakes are notoriously under-reported15. For 
these reasons, a proper correction for total energy intake is desired24,47.  
The inherent drawback of correcting the macronutrients for energy intake is that it can and likely 
does induce correlations between them: if an individual consumes more protein but holds total 
energy intake constant, he or she must consume relatively less energy from the other 
macronutrients. Hence, relative intake of one macronutrient indirectly represents a substitution 
effect of the other macronutrients24.  
However, we must point out that in our case induced correlations between macronutrients do not 
necessarily have to occur. To see this, consider first the simple case of two quantities 𝑃𝑃1 and 𝑃𝑃2, 
which add up to unity such that 𝑃𝑃1 + 𝑃𝑃2 = 1. Since we can write 𝑃𝑃2 = 1 − 𝑃𝑃1, then the 
correlation between 𝑃𝑃1 and 𝑃𝑃2 is 𝐶𝐶(𝑃𝑃1,𝑃𝑃2) = 𝐶𝐶(𝑃𝑃1, 1 − 𝑃𝑃1) =  −𝐶𝐶(𝑃𝑃1,𝑃𝑃1) =  −1 and thus 𝑃𝑃1 
and 𝑃𝑃2 are necessarily negatively correlated. However, if we have more than two phenotypes and 
𝑃𝑃1 + 𝑃𝑃2 + ⋯+ 𝑃𝑃𝑛𝑛 = 1, then the correlation between 𝑃𝑃1 and 𝑃𝑃𝑛𝑛 is 𝐶𝐶(𝑃𝑃1,𝑃𝑃𝑛𝑛) = 𝐶𝐶(𝑃𝑃1, 1 − 𝑃𝑃1 −
𝑃𝑃2 −⋯− 𝑃𝑃𝑛𝑛−1, and this holds for all combinations by permuting the indices. We thus see that 
these conditions can be satisfied for non-negative correlations between some pairs of 
phenotypes. The only necessity is that each macronutrient must be negatively correlated with at 
least one other macronutrient. 
In our case a missing piece of the total energy equation is alcohol, which is the final contributor 
to energy intake in European populations. Hence, the shares of protein, carbohydrate, and fat do 
not add up to unity. It is then theoretically possible that correlations between the macronutrients 
fat, protein and carbohydrate are all positive or zero but negatively correlated with relative 
alcohol intake. Finally, we note that SUGAR is a subset of CARBOHYDRATE and that SATURATED 
FAT is a subset of FAT, which imposes a positive correlation within these pairs. 
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We do identify genetic loci that are not shared (i.e., do not reach at least a level of suggestive 
genome-wide significance, with P > 1×10-5) by other macronutrients (Supplementary Table 
5.4). We could speculate that these loci regulate macronutrient-specific biological processes. 
However, loci that share association signal across multiple macronutrients may also still have 
direct biological effects on intake of only one of the macronutrients. For instance, loci with 
especially large effect sizes or small standard errors (e.g., because of more common allele 
frequency) might be associated with the other macronutrients, simply because the macronutrients 
are substituted for each other. This tends to be true in our case; associated loci with the lowest P 
values and highest explained phenotypic variances tend to share signal across macronutrients, 
while loci that are uniquely associated with one macronutrient tend to have larger P values and 
smaller explained phenotypic variances.  
We can illustrate this scenario with the following example. Assume that a locus specifically 
affects intake of sugar through modulation of sweet-taste preference. For simplicity, assume that 
sweet-taste preference is solely determined by this locus (i.e., is monogenic). If a person with the 
“sweet tooth” genotype then consumes more sugar than an individual without said genotype and 
holds intake of the other macronutrients constant (i.e., consumes the same total energy as the 
person without said genotype), we would measure a higher relative intake of sugar and a lower 
relative intake of the other macronutrients in this person’s dietary report. If sweet-toothed 
individuals spread their substitution across macronutrients, meaning that they do not 
systematically swap sugar for one other specific macronutrient compared to non-sweet-toothed 
individuals (i.e., swap sugar for a combination of other carbohydrates, fat, protein, and alcohol), 
the genotype will be associated mainly with sugar and to a lesser extent with the other 
macronutrients . However, if all sweet-toothed individuals would systematically swap sugar with 
fat, the locus would be equally associated with intake of both sugar and fat, and we could equally 
well describe the locus as a fatty-taste-preference locus. 
We could imagine a population of three sweet-toothed individuals (person A, B, and C) placing 
an order in a restaurant, where all order a sugary dessert. A fourth individual (person D) without 
the sweet-tooth genotype does not order a dessert, but consumes the same total number of 
calories as the three sweet-toothed individuals. To arrive at the same number of calories as 
person D, sweet-toothed person A might skip the hamburger (consume relatively less fat and 
protein); person B might skip the beer (consume relatively less alcohol), while person C might 
skip the fries (consume relatively less fat and non-sugar carbohydrates). This would describe a 
scenario where the increase in sugar is compensated with a pattern of substitutions across other 
macronutrients.  
If the sweet-tooth genotype has a large effect on sugar intake, the reduction in the other 
macronutrients will subsequently also be larger. The association test of the sweet-tooth genotype 
might then be well-powered to become associated with the non-sugar macronutrients, with the 
direction of effect being in the opposite direction to the effect for sugar. 
From correlational GWAS results, it might then be impossible to tell which macronutrient is 
directly regulated by the associated locus. This question would require experimental follow-up 
studies. For instance, FGF21 has been found to specifically regulate sugar and alcohol intake, 
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and to not respond to intake of bitter and fatty substances48. High FGF21 levels inhibit the desire 
to consume sugar48,49. However, FGF21 is also upregulated in response to protein restriction, 
triggering an adaptive metabolic response to starvation50. Hence, FGF21 might have a true 
pleiotropic role in both taste-preference regulation and adaptive metabolic response to protein-
restriction. In GWAS, the FGF21 locus is associated with all macronutrients. These findings 
illustrate the complex mechanisms that might underlie macronutrient intake, and underline the 
need for experimental follow-up research to elucidate GWAS associations. 
2.9 Correction for dieting 
In this study, we are interested in identification of genetic variants associated with habitual diet 
composition, and how these variants in turn relate to health and behavior. Importantly, we are not 
interested in genetic variants associated with diet composition in individuals on calorie- or 
macronutrient-restricted diets (RDs). For these individuals, reversed causal effects (i.e., health 
affecting diet and diet composition) are likely, and RDs are especially popular amongst 
overweight individuals. We therefore exclude individuals on any RDs when this information was 
available, and asked cohorts to do the same when this information was available, as detailed in 
our pre-registered analysis plan. The exclusion-criteria column in Supplementary Table 1.3 
lists whether cohorts were able to exclude individuals on RDs. 
3 GWAS, quality control and meta-analysis methods 
3.1 Genotyping and imputation 
Details of the cohort-specific sample sizes, genotyping and (pre-)imputation parameters, and 
filters can be found in Supplementary Table 1.3. 
In the discovery and replication cohorts analyzed in-house (FHS, HRS, RS, UKB, WHI), we 
preclude SNPs with low INFO-scores and low MAF from the GWAS in order to decrease 
computational effort. Overall, the preclusion filters are in rough accordance with the sample size 
dependent, post-GWAS QC-filters implemented by Karlsson Linnér et al51. For instance, in the 
UKB we do not perform GWAS on SNPs with MAF < 0.001 or INFO < 0.6 – which is in 
accordance with the preselected MAF ≥ 0.001 SNP filter for cohorts of N ≥ 10,000, and slightly 
more lenient than the INFO ≥ 0.7 SNP filter ultimately applied after the GWAS. We also 
residualize the GWAS phenotype on the covariates in a phenotypic regression, and use this 
residualized phenotype in the GWAS, instead of adding covariates to the GWAS regression 
(Supplementary Information 3.2.1). This further reduced GWAS runtime. 
At the participant-level, pre-GWAS exclusions vary by cohort, and were informed by: a low 
individual genotyping rate; sex mismatch; cryptic relatedness (with the exception of UKB and 
FHS, where related individuals were retained in the analysis and analyzed with mixed linear 
models as described in Supplementary Information 3.2.2); non-European ancestry; and (in 
some cohorts) aberrant or unexplained heterozygosity or chromosomal abnormalities or 
withdrawn informed consent (see Supplementary Table 1.3 for details). 
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3.2 Association analyses 
All analyses were performed at the cohort level according to a pre-specified and publicly 
archived analysis plan (available at https://osf.io/mt9kt/). The analysis plan specified that genetic 
discovery would be conducted in the UKB, and replication would be carried out in a meta-
analysis of all other cohorts. 
Within-cohort association analyses were performed on the 22 autosomes and exclusively in 
individuals of European ancestry. For the majority of cohorts, OLS regression was applied to 
unrelated individuals. Mixed linear models were applied to the discovery cohort and one of the 
replication cohorts (UKB and FHS, respectively) for related individuals, as described in 
Supplementary Information 0. 
The OLS association model was 
 𝑌𝑌𝑖𝑖 = 𝛽𝛽0 + 𝛽𝛽1𝑆𝑆𝑆𝑆𝑃𝑃𝑖𝑖 + 𝑷𝑷𝑷𝑷𝒊𝒊𝜸𝜸 + 𝑿𝑿𝒊𝒊𝜶𝜶 + 𝑷𝑷𝒊𝒊𝜽𝜽 + 𝜖𝜖𝑖𝑖, 
where 𝑌𝑌𝑖𝑖 is the unstandardized outcome, 𝑆𝑆𝑆𝑆𝑃𝑃𝑖𝑖 is the number of effect alleles [0, 1, 2] of the SNP; 
𝑷𝑷𝑷𝑷𝒊𝒊 is a vector of principal components of the variance-covariance matrix of the genotypic data 
(estimated on the basis of a QC’d selection of SNPs and individuals, and after the removal of 
long-range LD regions52); and 𝑿𝑿𝒊𝒊 is a vector of demographic control variables. These are sex, 
age, age2, sex × age, and sex × age2 and the number of dietary-intake observations (when 
applicable). 𝑷𝑷𝒊𝒊 is a vector of cohort-specific technical control variables. The exact set of 
covariates for each cohort can be found in Supplementary Table 3.1. In practice, we first 
residualized 𝑌𝑌𝑖𝑖 on all technical and demographic covariates, and then use this residualized 
phenotype in the GWAS; this was done for all cohorts analyzed by the Social Science Genetic 
Association Consortium (SSGAC; meaning UKB, and the replication cohorts FHS, HRS, RS, 
and WHI). In Supplementary Information 3.2.1, we show that this procedure does not inflate 
the false positive rate. 
The final maximum SNP-based sample sizes for GWAS discovery in the UKB are N = 264,181 
for FAT, PROTEIN and CARBOHYDRATE, and N = 230,648 for SUGAR. Replication is performed in a 
meta-analysis of 14 cohorts and summary statistics from the DietGen consortium. Prediction is 
performed with the coefficients from the full meta-analysis, but excluding the holdout cohort 
(RSI and HRS respectively). All other follow-up analyses are performed with the coefficients 
from the full meta-analysis (i.e., UKB, 14 replications cohorts, and DietGen).  
3.2.1 GWAS on a residualized phenotype, without further controls in the GWAS stage, is 
conservative 
As noted earlier, the GWAS in the cohorts UKB, FHS, HRS, RS, and WHI are performed on a 
phenotype that was residualized on the covariates. Here, we describe the statistical repercussions 
of this approach. 
Ideally, if one wants to eliminate the effects of a set of covariates on the outcome of interest prior 
to a GWAS, one should residualize both the regressors and outcome with respect to those 
covariates, as demanded by the Frisch–Waugh–Lovell (FWL) theorem. By only residualizing the 
19 
 
phenotype with respect to the covariates without residualizing the SNP data with respect to those 
same covariates, we effectively introduce a form of attenuation bias: we leave some noise in the 
genotypes—noise in the sense that there may be variation in the genotypes that is correlated with 
the covariates and that cannot be associated with the phenotype anymore after having 
residualized the phenotype with respect to those covariates. 
This attenuation bias of sorts shrinks our estimated SNP effects slightly towards zero—we say 
slightly, as we only expect considerable shrinkage for genotypes that correlate strongly with the 
covariates, but we expect only very few SNPs to have such a strong correlation. In addition, this 
attenuation bias, together with the fact that there effectively is noise left in the genotypes (as 
explained above), means that the GWAS has a slightly poorer fit than the proper approach 
stipulated by the FWL theorem. Hence, the residual variance may be slightly overestimated 
(except for the case of small N and a large number of covariates, where an incorrect number for 
the true degrees of freedom may bias the estimate of residual variance downwards—but this case 
is irrelevant in a typical GWAS setting, with large N). 
Combining the relevant pieces, it is now easy to show that, not only are the estimated SNP 
effects shrunken towards zero, but so are the t-test statistics. Consequently, our residualized 
approach is a computationally efficient approach that is conservative, yet sacrifices only a 
minuscule amount of statistical power, as we show below. 
Importantly, we do require all relevant variables to be mean-centered. That is, the outcome 
should be corrected for the linear effects of the covariates as well as an intercept (if not included 
as a covariate directly), and the GWAS itself should still control for an intercept, even if other 
covariates are not included. 
Now, for a GWAS with covariates in matrix Z with effects 𝛄𝛄, we show that residualization of the 
phenotype, y, with respect to the covariates, Z, without including those covariates in the GWAS 
stage, can only bias the GWAS estimate of a SNP’s effect, ?̂?𝛽, and its t-test statistic towards 
smaller magnitude. 
For ease of notation, let us consider only one SNP, x (so no SNP index is required). The model 
specification is given by 
𝐲𝐲 = 𝐱𝐱𝛽𝛽 + 𝐙𝐙𝛄𝛄 + 𝛆𝛆, 
where 𝛆𝛆 is the error term. 
By the Frisch–Waugh–Lovell theorem, the OLS estimate of the SNP effect is now given by 
?̂?𝛽 = (𝐱𝐱′𝐌𝐌𝐙𝐙𝐱𝐱)−1𝐱𝐱′𝐌𝐌𝐙𝐙𝐲𝐲, where  𝐌𝐌𝐙𝐙 = 𝐈𝐈 − 𝐙𝐙(𝐙𝐙′𝐙𝐙)−𝟏𝟏𝐙𝐙′ 
where the latter is a projection matrix, that removes the linear effects of Z to whatever vector it is 
applied to (in this case, x and y). 
Instead of including these covariates in the GWAS, we partial out the effects of Z on y (i.e., we 
take 𝐲𝐲∗ = 𝐌𝐌𝐙𝐙𝐲𝐲) and then regress 𝐲𝐲∗ on x. This implies that our residual-based GWAS estimate 
of 𝛽𝛽 is given by 
𝛽𝛽∗� = (𝐱𝐱′𝐱𝐱)−1𝐱𝐱′𝐲𝐲∗ = (𝐱𝐱′𝐱𝐱)−1𝐱𝐱′𝐌𝐌𝐙𝐙𝐲𝐲. 
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Noting that 𝐌𝐌𝐙𝐙 is symmetric and positive semidefinite, it holds that (𝐱𝐱′𝐌𝐌𝐙𝐙𝐱𝐱) ≥ 𝟎𝟎. Moreover, as 
𝐌𝐌𝐙𝐙 eliminates some of the variation in x, it also holds that (𝐱𝐱′𝐱𝐱) ≥ (𝐱𝐱′𝐌𝐌𝐙𝐙𝐱𝐱). Consequently 
(𝐱𝐱′𝐱𝐱) ≥ (𝐱𝐱′𝐌𝐌𝐙𝐙𝐱𝐱) ≥ 𝟎𝟎  
⇔ 0 ≤ (𝐱𝐱′𝐱𝐱)−𝟏𝟏 ≤ (𝐱𝐱′𝐌𝐌𝐙𝐙𝐱𝐱)−𝟏𝟏 
⇔ 0 ≤ (𝐱𝐱′𝐱𝐱)−𝟏𝟏|𝐱𝐱′𝐌𝐌𝐙𝐙𝐲𝐲| ≤ (𝐱𝐱′𝐌𝐌𝐙𝐙𝐱𝐱)−𝟏𝟏|𝐱𝐱′𝐌𝐌𝐙𝐙𝐲𝐲| 
⇒ 0 ≤ �(𝐱𝐱′𝐱𝐱)−𝟏𝟏𝐱𝐱′𝐌𝐌𝐙𝐙𝐲𝐲� ≤ �(𝐱𝐱′𝐌𝐌𝐙𝐙𝐱𝐱)−𝟏𝟏𝐱𝐱′𝐌𝐌𝐙𝐙𝐲𝐲� 
⇔ 0 ≤ �𝛽𝛽∗�� ≤ �?̂?𝛽�. 
Hence, the OLS estimate from the regression of the residualized phenotype on the original SNP 
has a magnitude that is smaller than or equal to the magnitude of OLS estimate of the regression 
of the original phenotype on the SNP, controlling for the covariates in that regression. Moreover, 
as the sign of the two respective estimators is determined only by 𝐱𝐱′𝐌𝐌𝐙𝐙𝐲𝐲, it holds that sign(𝛽𝛽∗�) = 
sign(?̂?𝛽). Hence, residualization merely reduces the magnitude of the estimator without changing 
the sign. 
Regarding t-test statistics used for our inferences, it holds that 
𝑐𝑐 = (𝐱𝐱′𝐌𝐌𝐙𝐙𝐱𝐱)1/2?̂?𝛽/𝜎𝜎� and 𝑐𝑐∗ = (𝐱𝐱′𝐱𝐱)1/2𝛽𝛽∗�/𝜎𝜎∗� 
Hence, 
𝑐𝑐 = (𝐱𝐱′𝐌𝐌𝐙𝐙𝐱𝐱)−1/2𝐱𝐱′𝐌𝐌𝐙𝐙𝐲𝐲/𝜎𝜎�  and  𝑐𝑐∗ = (𝐱𝐱′𝐱𝐱)−1/2𝐱𝐱′𝐌𝐌𝐙𝐙𝐲𝐲/𝜎𝜎∗�, 
where 𝜎𝜎� and 𝜎𝜎∗� are the estimators of standard deviation of 𝛆𝛆, described next. 
If x and Z were orthogonal (i.e. 𝐙𝐙′𝐱𝐱 = 𝟎𝟎), the regression residuals, 𝐞𝐞, resulting from the 
regression of y on x and Z jointly would be identical to the residuals, 𝐞𝐞∗, from the regression of 




√𝐞𝐞′𝐞𝐞    and    𝜎𝜎� =
1
√𝑆𝑆 − 𝐶𝐶 − 1
√𝐞𝐞′𝐞𝐞, 
where C is the number of regressors in Z and N the number of observations. Therefore, 
𝜎𝜎∗� = �
𝑆𝑆 − 𝐶𝐶 − 1
𝑆𝑆 − 1
𝜎𝜎�. 
Hence, provided 𝑆𝑆 ≫ 𝐶𝐶 (which should be the case) and orthogonal genotypes and 
covariates, 𝜎𝜎∗� ≈ 𝜎𝜎�. In case, however, there is some correlation between x and Z, we have that 
√𝐞𝐞′𝐞𝐞 ≤ √𝐞𝐞∗′𝐞𝐞∗, in which case (again provided 𝑆𝑆 ≫ 𝐶𝐶), by good approximation, it follows that 
𝜎𝜎∗� ≥ 𝜎𝜎�. 
In the same way we showed that �𝛽𝛽∗�� ≤ �?̂?𝛽�, we can show that 
�(𝐱𝐱′𝐱𝐱)−𝟏𝟏/𝟐𝟐𝐱𝐱′𝐌𝐌𝐙𝐙𝐲𝐲� ≤ �(𝐱𝐱′𝐌𝐌𝐙𝐙𝐱𝐱)−𝟏𝟏/𝟐𝟐𝐱𝐱′𝐌𝐌𝐙𝐙𝐲𝐲�. 
 
Hence, �(𝐱𝐱′𝐱𝐱)−𝟏𝟏/𝟐𝟐𝐱𝐱′𝐌𝐌𝐙𝐙𝐲𝐲/𝜎𝜎∗�� ≤ �(𝐱𝐱′𝐌𝐌𝐙𝐙𝐱𝐱)−𝟏𝟏/𝟐𝟐𝐱𝐱′𝐌𝐌𝐙𝐙𝐲𝐲/𝜎𝜎�� (approximately) and therefore |𝑐𝑐∗| ≤
|𝑐𝑐| (approximately). Moreover, as with the estimates of 𝛽𝛽, we have that sign(𝑐𝑐∗) = sign(𝑐𝑐). 
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Consequently, the GWAS t-test statistic for a SNP, using a phenotype that has been residualized 
with respect to the covariates prior to the GWAS, without inclusion of those same covariates in 
the GWAS itself, provides a credible, conservative lower bound to the GWAS t-test statistic 
including the covariates. 
We note that even when x and Z are completely orthogonal—in which case test statistics are 
inflated under our approach—for typical values of N and C, the inflation is negligible, as can be 
seen in Supplementary Table 3.2. For example, even in a sample of 50,000 observations in a 
study with 100 covariates, the inflation in test statistics of any given SNP is at most 0.10%. Now, 
considering the P value of a SNP that is not correlated with any of the covariates and has a P 
value around the level of genome-wide significance in this sample: if the estimated SNP effect is 
just genome-wide significant here (i.e., |t| = 5.453, with P value = 4.976×10−8 under 49,899 
degrees of freedom), the maximum possible inflation would only increase |t| by 0.10% and 
decrease the P value by 1.65×10−9 (i.e., we then have |t *| = 5.459 with P value = 4.811×10−8 
under 49,999 degrees of freedom). 
To summarize, our approach has a strong tendency to be conservative in terms of the inferences 
we make. The more strongly a SNP is correlated with the covariates, the more conservative our 
inferences will be. Moreover, even for the SNPs for which our approach inflates the magnitude 
of the test statistics, this inflation is negligible for realistic sample sizes and number of 
covariates. 
3.2.2 Linear mixed model association analysis 
As noted earlier, we perform GWAS in FHS and UKB with linear mixed models (LMMs). We 
do this to leverage information from the substantial numbers of (cryptically) related individuals 
in these cohorts. An additional benefit is that LMM analysis also performs a better correction for 
population stratification than can be achieved with the use of a limited number of PCs53. 
However, we still residualize the phenotypes on 10 and 20 PCs, respectively, prior to performing 
GWAS.  
Both cohorts calculated their own set of PCs on the basis of a selection of high quality, 
independent SNPs, and unrelated individuals. For UKB, the procedure is described in the 
Supplementary Materials of Bycroft et al.54.  For both UKB and FHS, we calculate the median 
“effective sample size” (as described in Supplementary Information 3.4.1) across the SNPs 
that were retained after quality control. This median effective sample size forms the meta-
analysis weight in our N-weighted meta-analysis of SNP effects (Supplementary Information 
3.4). 
UKB 
In UKB, we performed GWAS with BOLT-LMM software v2.253. In the genetic variance 
component, we included 723,483 directly genotyped bi-allelic SNPs with MAF > 0.001, and 
SNP call rate > 0.9. In accordance with the protocol used in Karlsson Linnér et al.51, we only 
included individuals of self-reported European ancestry (i.e., British, Irish, or any other 
European background) whose PC score on the first PC of the genotype matrix was less than 0, as 
this identified a cluster of individuals of European ancestry. This cutoff was based on visual 
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inspection of the histogram of the first PC, which clearly demarcates individuals of European 
ancestry from the other ancestries. Both in this quality control procedure and in the GWAS, we 
make use of the PCs that were calculated by UKB54 on the basis of the full UKB sample (which 
included individuals from all ancestries) with fastpca55 software. Other participant filters are 
reported in Supplementary Table 1.3. 
FHS 
In FHS, we performed linear mixed model association with the use of GCTA56. Here, we 
implemented MLMA-LOCO57, or “Mixed Linear Model Association – Leave One Chromosome 
Out”. This procedure removes the chromosome on which the focal SNP is located from the 
genetic relatedness matrix. The analysis excluded SNPs with MAF < 0.01, and individuals with 
with genotyping call rate < 0.95. 
3.2.3 Auxiliary GWAS 
In addition to the sex-pooled GWAS of the four macronutrients, we also perform sex-stratified 
GWAS of the four macronutrients in the UKB and a sex-pooled GWAS for relative saturated-fat 
intake (“SATURATED FAT”) in the UKB. For the sex-stratified GWAS, we perform LDSC genetic 
correlation analyses to assess whether the genetic architecture of diet composition is sex-specific. 
For SATURATED FAT, we assess the genetic correlations with the other macronutrients as well as 
genetic correlations with other traits. 
3.3 Quality control 
3.3.1 Reference panel 
The reference panel used throughout this project for SNP-based quality control and LD 
calculations is based on the v1.1 release from the Haplotype Reference Consortium58 (HRC, 
downloaded from the European Genome-phenome Archive on August 1, 2017), with genomic 
positions aligned to Genome Reference Human genome build 37 (GRCh37). Details on how this 
reference panel was constructed can be found in Karlsson Linnér et al.51. In brief, an internal 
quality control procedure removed any non-autosomal SNPs, SNPs with duplicate SNP 
positions, multi-allelic SNPs, or strand inconsistencies with the UK10K59 haplotype reference 
panel. Subsequently, one individual of a cryptic pair (genetic relatedness > 0.025) was removed, 
as implemented with the use of PLINK 1.960,61. Finally, the total sample size in this reference 
panel is N = 17,774, containing 38,889,224 bi-allelic autosomal SNPs that passed internal QC. 
3.3.2 Cohort-level quality control  
Post-GWAS, pre-meta-analysis quality control (QC) at the cohort-specific summary statistics 
level was performed with EasyQC software62. In accordance with QC-protocols from Winkler et 
al.62 and the SSGAC63,64, genetic variants were removed if they met any of the following criteria: 
1. Missing values for: the effect or non-effect allele, MAF, N, beta, standard error, INFO-
score, allele frequency, or the imputed/genotyped indicator; 
2. Nonsensical values (e.g., P value < 0 or MAF > 1, imputation-quality score > 1; negative 
or infinite betas or standard errors). 
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3. More than one coded allele (indicative of a structural variant) or reported structural 
variants (e.g., indels);  
4. Low minor allele frequency (MAF); 
5. Low SNP call rate;  
6. Low imputation-quality INFO-score; 
7. Low P value for the Hardy-Weinberg Equilibrium test (if available); 
8. Absence (or mismatched) alleles with respect to our HRC reference panel; 
9. Explained variance for the SNP in the phenotype (R2) of higher than 5%, based on the 
SNP’s MAF and phenotype’s standard deviation; 
10. Standard error for the SNP that was 1.4 times higher than expected based on the SNP’s 
MAF and phenotype’s standard deviation. 
A number of these parameters vary by cohort as a function of cohort sample size; the cohort-
specific details can be found in Supplementary Table 1.3. Supplementary Table 3.3 lists, for 
each cohort, the number of SNPs that entered the quality control procedure and the number 
dropped at each step.  
For the DietGen consortium summary statistics, the filters 9 and 10 could not be applied because 
we do not have access to the phenotypes’ pooled standard deviations. In the UKB, we also drop 
all SNPs not imputed to the HRC panel, as these were not aligned properly to their genomic 
coordinates in the second release of the UKB of July 2017c. 
After filtering out low-quality SNPs, we visually inspected diagnostic plots generated by 
EasyQC to flag potentially remaining QC issues. These were generated separately for each 
cohort. 
Of interest are: 
1. Q-Q plots, to inspect excessive inflation (“early liftoff”) of P values due to remnant 
population stratification; 
2. Allele frequency plots, which compare the observed allele frequency in the cohort to the 
allele frequency in our HRC reference panel. Large or systematic discrepancies could 
indicate, for instance, strand issues (e.g., ‘allele flips’) or inadequate filtering of ancestry 
outliers. Note that we used this plot to detect systematic errors, but we did not actually 
remove any large MAF outliers with respect to the reference panel. 
The other EasyQC plots (SE-N plots, P-Z plots) were also used to detect potential internal 
analytical errors. Finally, we also generated a plot that compared the expected SNP effect 
standard errors (for a random sample of 10,000 SNPs, based on the reported phenotype’s 
standard deviation) to the reported SNP effect standard errors. This plot was used to assure that 






3.3.3 Post meta-analysis QC 
After meta-analysis was performed, we remove SNPs that were available in less than 50% of the 
phenotype-specific total maximum sample size. 
3.3.4 Locus definition 
Since the human genome is characterized by widespread LD between SNPs, significantly 
associated SNPs generally tend to cluster with other significantly associated SNPs within the 
same genomic region. When one of these regions carries a SNP that reaches genome-wide 
significance, we call this region the associated locus. The SNP with the lowest P value in that 
locus is deemed the “lead SNP”. (The lead SNP is not necessarily the causal variant in the locus; 
it may just be the most accurately genotyped or imputed variant in that particular region.) 
In order to establish the number of independently associated loci for the traits in this study, we 
use the “clumping” algorithm in PLINK61, which ascertains the set of SNPs that are in LD with 
the lead SNP (as based on calculations in our HRC reference panel). PLINK first takes the SNPs 
that reach genome-wide significance, and then “clumps” SNPs in their genomic region into its 
locus. Inclusion of SNPs into a “clump” (i.e., independent genomic region) is based on an LD 
threshold (in our case, r2 = 0.1, which is the squared correlation of the lead SNP with the SNPs in 
its vicinity), association with the phenotype at some P value threshold (in our case, P < 0.01, 
which is mainly implemented to remove SNPs from the clumps to drastically decrease the 
algorithm’s runtime), and genomic distance. In our case, we set the genomic distance parameter 
to be 100,000,000 kilobases (kb), effectively making the LD- and P value-thresholds the only 
binding parameters. 
3.4 Meta-analysis 
3.4.1 Meta-analysis scheme 
Fixed effects meta-analysis of SNP effects (i.e., SNP Z-scores) is performed with METAL65 
software, using a sample size weighting scheme. Sample size weighting is performed at the level 
of the SNP’s Z-statistics across cohorts, where the SNP’s overall Z-score for SNP i across 
cohorts J can be defined as 








where the weight for cohort j is defined as 
𝑤𝑤𝑗𝑗 =  �𝑆𝑆𝑗𝑗 . 
For the two cohorts that used a mixed linear model (in which related individuals were included), 








where 𝑆𝑆𝐷𝐷𝑌𝑌2 is the variance in phenotype 𝑌𝑌 and 𝑆𝑆𝐸𝐸𝑖𝑖,𝑗𝑗 is the unstandardized standard error for SNP 
i in cohort j. For each cohort’s meta-analysis weight, we use the median effective sample size 
across quality-controlled SNPs J. 
Throughout this study, we measure the SNP effect size by the semi-standardized beta 
(?̂?𝛽𝑖𝑖, described next) and the explained variance in the phenotype by the incremental adjusted R2 . 
We calculate the incremental adjusted  R2 by first regressing the phenotype on a set of covariates 
(described in more detail in Supplementary Information 9.1), and then estimating the same 
regression with the phenotype’s polygenic score as an additional covariate. The difference in 
adjusted R2 between the two models is the incremental adjusted R2 which thus denotes the 
additional explained phenotypic variance from the genotype after accounting for covariates that 
are included in the GWAS (or residualized from the phenotype). The semi-standardized beta is 
standardized with respect to the phenotype but not with respect to the genotype; it is the effect 
size in standard deviations of the phenotype per effect allele. The semi-standardized beta is 
calculated using the approximation (as derived in the Supplementary Note from Rietveld et al.66, 
page 5) 
?̂?𝛽𝑖𝑖 = 𝑍𝑍𝑖𝑖 ×  𝑆𝑆𝐸𝐸𝑖𝑖, 
where the Z-score for SNP i is estimated in the meta-analysis, and the semi-standardized 
standard error for SNP i is calculated as 
𝑆𝑆𝐸𝐸𝑖𝑖 =  ��2 × 𝑆𝑆𝑖𝑖 × 𝑀𝑀𝑀𝑀𝐹𝐹𝑖𝑖 × (1 −𝑀𝑀𝑀𝑀𝐹𝐹)�
−1
. 
The incremental R2 for SNP i is then calculated using the approximation 
𝑅𝑅𝑖𝑖2 = 2 × 𝑀𝑀𝑀𝑀𝐹𝐹𝑖𝑖 × (1 −𝑀𝑀𝑀𝑀𝐹𝐹𝑖𝑖) × 𝛽𝛽𝚤𝚤 �2. 
To correct the inflation of SNP estimates for population stratification, we supply METAL65 with 
the intercepts obtained from LD Score regression67. METAL then deflates the SNP’s Z-statistics 







4.1 Genetic correlations between discovery and replication cohorts 
We use bivariate LD Score regression (method described in Supplementary Information 10) to 
examine the comparability between the summary statistics from our discovery cohort, the 14 
replication cohorts, and DietGen (where the latter two make up our combined replication phase). 
The results are reported in Supplementary Table 4.1. 
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4.1.1 Discovery vs. 14 replication cohorts 
We find the genetic correlation between our discovery and 14 replication cohorts is statistically 
significantly greater than 0 for all phenotypes. Further, we fail to reject the hypothesis that the 
genetic correlation is unity for FAT (?̂?𝑐𝑔𝑔= 0.997), CARBOHYDRATE (?̂?𝑐𝑔𝑔= 1.14d) and SUGAR (?̂?𝑐𝑔𝑔= 
0.997). We find a genetic correlation of less than 1 (but greater than 0) for PROTEIN (?̂?𝑐𝑔𝑔= 0.686), 
which implies that the predictive power of the protein polygenic score will be lower than 
expected based on theoretical calculations that assume a perfect genetic correlation. 
4.1.2 Discovery and 14 replication cohorts vs. DietGen 
We also examine the genetic correlations between DietGen and (1) the 14 replication cohorts and 
(2) the discovery cohort and 14 replication cohorts meta-analyzed together. We find strong 
positive genetic correlations for all phenotypes: FAT (?̂?𝑐𝑔𝑔= 0.78, SE = 0.18), PROTEIN (?̂?𝑐𝑔𝑔= 0.88, SE 
= 0.19) and CARBOHYDRATE (?̂?𝑐𝑔𝑔= 0.71, SE = 0.12). Further, we fail to reject the null hypothesis 
(at the 1% significant level) that this genetic correlation is different from 1 for all phenotypes, 
although CARBOHYDRATE is significantly different from 1 at the 5% level. When we compare the 
DietGen results to only our 14 replication cohorts meta-analyzed together (i.e., without the 
discovery phase) we find strong genetic correlations that are statistically indistinguishable from 
unity (P value > 0.25), with ?̂?𝑐𝑔𝑔= 1.21 (SE = 0.31) for FAT, ?̂?𝑐𝑔𝑔= 0.75 (SE = 0.22) for PROTEIN, and 
?̂?𝑐𝑔𝑔= 0.82 (SE = 0.20) for CARBOHYDRATE. We conclude that our results are broadly consistent 
with the most similar previous study. 
4.1.3 Discovery vs. full replication phase 
We also report the genetic correlations between the discovery and full replication phase (where 
the “full replication phase” consists of the 14 cohorts and DietGen). Here, we find an especially 
high correlation for CARBOHYDRATE (?̂?𝑐𝑔𝑔= 0.98, SE = 0.10) which is statistically indistinguishable 
from unity and smaller correlations for FAT (?̂?𝑐𝑔𝑔= 0.79, SE = 0.09) and PROTEIN (?̂?𝑐𝑔𝑔= 0.77, SE = 
0.10), which are significantly different from 1 at the 5% level.  
4.1.4 EPIC-InterAct vs. full meta-analysis 
Finally, we report the genetic correlation between the two EPIC-InterAct cohorts meta-analyzed 
(combined N = 12,722) and all other remaining cohorts meta-analyzed (combined N = 222,669) 
for SUGAR, since the two EPIC-InterAct cohorts analyzed added sugars instead of total sugars 
(Supplementary Information 2.3). We find that the genetic correlation does not differ 
significantly from 0 nor 1 (?̂?𝑐𝑔𝑔= 0.71, SE = 0.47), indicating that this genetic correlation analysis 
is underpowered at the current EPIC-InterAct sample size. However, we note that we find one 
additional GWAS hit for SUGAR after including the two EPIC-InterAct cohorts, reflecting the 
small increase in power for genetic discovery with the addition of EPIC-InterAct. 
 
 




The results show that the 14 replications cohorts correlate very highly with the discovery cohort 
for FAT, CARBOHYDRATE and SUGAR. For PROTEIN, the correlation is significantly different from 
1, suggesting decreased power to replicate individual SNPs in these cohorts. When we add 
DietGen to the 14 cohorts (giving rise to our full replication phase), we see that the genetic 
correlation increases for PROTEIN, slightly decreases for CARBOHYDRATE, and decreases 
moderately for FAT. This indicates that with the addition of the DietGen cohort, we especially 
gain power for genetic discovery and replication for PROTEIN and CARBOHYDRATE, but less so for 
FAT.  
Aside from differences in population characteristics, differences between the discovery and 14 
replication cohorts may be driven by the fact that the discovery cohort used a different diet 
questionnaire method than the replication cohorts (24HDR vs. FFQ, see Supplementary 
Information 2.5.1), while differences between the discovery cohort (and the 14 replication 
cohorts) and DietGen may be driven by differing phenotype definitions (see Supplementary 
Information 2.6). Even given these imperfect genetic correlations at the 5% level, we stress that 
meta-analyzing with highly genetically (yet imperfect) correlated data still gives us an advantage 
in terms of statistical power for genetic discovery. This power tradeoff between quality (in terms 
of harmonized phenotypes) and quantity (in terms of sample size) has been described in detail in 
previous work63,68. 
4.2 Replication of GWAS hits from the discovery stage 
In this section, we discuss the GWAS findings from the discovery stage, and we assess the 
credibility of the results from our discovery GWAS by replicating the associations of its lead 
SNPs in our replication GWAS of the same phenotypes. As planned at the inception of this study 
(and pre-registered in our analysis plan on Open Science Framework, https://osf.io/mt9kt/), we 
use the UK Biobank as our discovery cohort and all the other cohorts as replication samples that 
we then meta-analyze together. We begin by describing the methods for replication analyses, 
followed by the replication results and how they compare to expected replication rates. In the 
final subsection, we demonstrate that we do not lose much statistical power by splitting the total 
sample into the UKB as discovery and the rest as replication, compared to the optimal split 
calculated from simulations. 
4.2.1 Methods 
General methods 
Our replication analyses closely follow the procedure outlined in Supplementary Information 
section 1.8 of Okbay et al.64. We use binomial tests to assess whether the independent lead SNPs 
from our discovery GWAS replicate in an independent replication GWAS. Under the null 
hypothesis that each of the lead SNPs is null in both the discovery and replication sample, we 
would expect 50% of the SNPs to have concordant signs and 5% to be statistically significantly 
different at the 5% level. Hence, it follows that the number of SNPs that have concordant signs 
or that are above a certain significance threshold is distributed as Binomial (M, π), where M is 
28 
 
the total number of independent lead SNPs and π is the expected fraction of sign-concordant or 
significant SNPs. We conduct one-sided binomial tests for both the sign concordance of the lead 
SNPs and the number of lead SNPs from our discovery GWAS that are statistically significantly 
different at the 5% level (both with and without Bonferroni correction) in the replication GWAS. 
The Bonferroni-corrected P value threshold is determined separately for each phenotype as 0.05 
divided by the number of lead SNPs from the discovery GWAS for that phenotype. 
We use the UKB data as our discovery sample. While most of the independent lead SNPs 
identified in the discovery GWAS are directly available in the replication GWAS, we find that 
one of the lead SNPs for CARBOHYDRATE was missing in the replication sample. For this missing 
lead SNP, we replace it with a suitable proxy that satisfied the following conditions: i) the SNP is 
available in both the discovery GWAS and the replication GWAS, ii) the SNP is within 500 kb 
of the original lead SNP in the discovery sample, and iii) the SNP has the lowest P value in the 
discovery GWAS among those that satisfy i) and ii). Specifically, we replace lead SNP 
rs7502280 with rs2435204 (r2 = 0.487). 
Calculation of expected replication records 
In addition to conducting binomial tests, we calculate the expected rate of replication (given the 
discovery GWAS results, the discovery sample size and the replication sample size) using 
simulations, and we assess whether these expected rates matched the observed replication rates. 
The results from these analyses might be more informative than the binomial tests, since the null 
hypothesis in the binomial tests posits zero association in the replication sample (which is 
unlikely, given the high genetic correlation between the discovery and replication results, as 
shown in Supplementary Table 4.2). Moreover, since the number of lead SNPs in the discovery 
sample is relatively small, the binomial tests do not have much power to reject the null 
hypothesis. 
Following the procedure outlined in Okbay et al.64, we first conduct a Bayesian Winner’s Curse 
correction to obtain estimates of the posterior distribution of the SNPs’ true effect sizes, given 
their GWAS estimates. Given this estimate of the posterior distribution, we then conduct 
simulations to compute the expected sign concordance and replication record. In each of our 
10,000 simulations, we draw a true effect size (𝛽𝛽𝑗𝑗) for each SNP j from the estimated posterior 
distribution and added Gaussian noise to generate discovery and replication GWAS estimates for 
each SNP as follows: 
?̂?𝛽𝐷𝐷𝑖𝑖𝑠𝑠𝑖𝑖𝑜𝑜𝑜𝑜𝑖𝑖𝑠𝑠𝑠𝑠,𝑗𝑗 = 𝛽𝛽𝑗𝑗 + 𝜖𝜖𝑗𝑗𝜎𝜎�𝐷𝐷𝑖𝑖𝑠𝑠𝑖𝑖𝑜𝑜𝑜𝑜𝑖𝑖𝑠𝑠𝑠𝑠,𝑗𝑗 
?̂?𝛽𝑅𝑅𝑖𝑖𝑖𝑖𝑅𝑅𝑖𝑖𝑖𝑖𝑠𝑠𝑠𝑠𝑖𝑖𝑜𝑜𝑛𝑛,𝑗𝑗 = 𝛽𝛽𝑗𝑗 + 𝛿𝛿𝑗𝑗𝜎𝜎�𝑅𝑅𝑖𝑖𝑖𝑖𝑅𝑅𝑖𝑖𝑖𝑖𝑠𝑠𝑠𝑠𝑖𝑖𝑜𝑜𝑛𝑛,𝑗𝑗, 
where 𝜖𝜖𝑗𝑗 and 𝛿𝛿𝑗𝑗 are independently drawn from a standard normal distribution, and the standard 
deviations of the estimation error can be approximated as 𝜎𝜎�𝐷𝐷𝑖𝑖𝑠𝑠𝑖𝑖𝑜𝑜𝑜𝑜𝑖𝑖𝑠𝑠𝑠𝑠,𝑗𝑗 ≈ 1/√𝑆𝑆𝐷𝐷𝑖𝑖𝑠𝑠𝑖𝑖𝑜𝑜𝑜𝑜𝑖𝑖𝑠𝑠𝑠𝑠 and 
𝜎𝜎�𝑅𝑅𝑖𝑖𝑖𝑖𝑅𝑅𝑖𝑖𝑖𝑖𝑠𝑠𝑠𝑠𝑖𝑖𝑜𝑜𝑛𝑛,𝑗𝑗 ≈ 1/√𝑆𝑆𝑅𝑅𝑖𝑖𝑖𝑖𝑅𝑅𝑖𝑖𝑖𝑖𝑠𝑠𝑠𝑠𝑖𝑖𝑜𝑜𝑛𝑛. Then, we record the number of SNPs that are concordant in 
sign and also the number of SNPs that replicate with the same sign at the 5% level (both with 
and without Bonferroni correction). Finally, we obtain the expected sign concordance and the 




Supplementary Table 4.2 summarizes the results, and Extended Data Figure 3 compares the 
effect sizes (and 95% confidence intervals) of the lead SNPs that reached genome-wide 
significance in the discovery phase to their effect sizes observed in the replication phase.  
In this discovery GWAS of our four phenotypes – FAT, PROTEIN, SUGAR, and CARBOHYDRATE – 
we found 4, 5, 5 and 7 independent lead SNPs, respectively. The independent lead SNPs were 
obtained by clumping the GWAS summary statistics using the Haplotype Reference Consortium 
(HRC) reference panel with the thresholds defined in Supplementary Information 3.3.4. After 
taking overlapping loci between phenotypes into account, we identify 12 unique loci discovered 
in the UKB. 
Overall, three of our four macronutrients – PROTEIN, SUGAR, and CARBOHYDRATE – reject the 
null hypothesis of (random) 50% sign concordance, while all four macronutrients reject the null 
hypothesis of no association even after phenotype-specific Bonferroni correction for the number 
of associated lead SNPs in the discovery stage. In addition, the observed number of SNPs that 
match in signs and the observed number of SNPs that are statistically significant are close to 
their theoretical predictions using the simulation procedure described above. 
FAT. Among the four independent lead SNPs identified from the discovery GWAS, all have 
matching signs, three of them are significantly different from zero at the 5% level, and two of 
them are significant at the Bonferroni-corrected 5% level in the replication sample. Using a 
Binomial test with distribution (4, π) where π is the expected fraction of sign-concordant or 
significant SNPs, we can construct P values associated with these results as described in section 
4.1.1. The P value associated with the sign concordance is then 0.063, the P value associated 
with the number of SNPs significant at the 5% level is <0.001, and the P value associated with 
the number of SNPs significant at the Bonferroni-corrected 5% level is <0.001.  Our calculation 
for expected replication indicates that 3.7 SNPs (95% CI 3.0 to 4.0) are expected to have 
concordant signs, 2.0 SNPs (95% CI 0 to 4.0) are expected to be significant at the 5% level and 
1.3 SNPs (95% CI 0 to 3.0) are expected to be significant at the Bonferroni-corrected 5% level. 
Comparing these to the observed numbers—4, 3, and 2, respectively—shows that the replication 
record of our lead SNPs is close to what we would expect, given our discovery GWAS estimates 
and discovery and replication sample sizes. 
PROTEIN. All of the five lead SNPs from the discovery GWAS have concordant signs, and four of 
them are significant at both the 5% level and the Bonferroni-corrected 5% level in the replication 
sample. The P value associated with the sign concordance is 0.031, the P value associated with 
the number of SNPs significant at the 5% level is <0.001, and the P value associated with the 
number of SNPs significant at the Bonferroni-corrected 5% level is <0.001. Our calculation for 
expected replication indicates that 4.4 SNPs (95% CI 3.0 to 5.0) are expected to have matching 
signs, 1.9 SNPs (95% CI 0 to 4.0) are expected to be significant at the 5% level and 1.0 SNP 
(95% CI 0 to 3.0) is expected to be significant at the Bonferroni-corrected 5% level. The 
observed numbers (i.e. 5, 4, and 4, respectively) surpass these expectations and show that the 
replication record was stronger than predicted. 
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SUGAR. All of the five lead SNPs from the discovery GWAS have concordant signs and are 
significant at the 5% level and the Bonferroni-corrected 5% level in the replication sample. The 
P value associated with the sign concordance is 0.031, the P value associated with the number of 
SNPs significant at the 5% level is <0.001, and the P value associated with the number of SNPs 
significant at the Bonferroni-corrected 5% level is <0.001. Our calculation for expected 
replication indicates that we are expected to see 4.3 SNPs (95% CI 3.0 to 5.0) that match in 
signs, 1.3 SNPs (95% CI 0 to 3.0) that are significant at the 5% level and 0.5 SNPs (95% CI 0 to 
2.0) that are significant at the Bonferroni-corrected 5% level. The observed numbers (i.e. 5, 5, 
and 5, respectively) are all above these expected numbers. 
CARBOHYDRATE. Among the seven lead (or proxy-lead) SNPs, we found that all seven of them 
have concordant signs, three of them are significant at both the 5% level and the Bonferroni-
corrected 5% level in the replication sample. The P value associated with the sign concordance is 
0.008, the P value associated with the number of SNPs significant at the Bonferroni-corrected 
5% level is 0.004, and the P value associated with the number of SNPs significant at the 
Bonferroni-corrected 5% level is <0.001. Our calculation for expected replication indicates that 
6.8 SNPs (95% CI 6.0 to 7.0) are expected to have concordant signs, 4.4 SNPs (95% CI 2.0 to 
7.0) are expected to be significant at the 5% level and 2.6 SNPs (95% CI 0 to 5.0) are expected 
to be significant at the Bonferroni-corrected 5% level. The observed numbers (i.e. 7, 3 and 3, 
respectively) show that the replication record of our lead SNPs is close to expectation. 
Ex post analysis of statistical power for replication 
At the inception of this study, we decided to use the UKB as the discovery sample and all 
additional recruited cohorts as the replication sample. Despite some potential loss in statistical 
power, we believed that doing so would make our study more transparent and not dependent on 
how we split the total sample for discovery and replication. In this subsection, we calculate the 
optimal split and gauge our loss in statistical power through simple simulations that are similar in 
nature to the simulations used for calculating the expected replication record described above. 
We first obtain estimates of the distribution of the SNPs’ true effect sizes, conditioning on the 
fraction of total sample size used as replication sample and using some key summary statistics 
from GWAS results of all cohorts meta-analyzed. We assume a “spike-and-slab” mixture 
distribution of effect sizes, where a fraction of SNPs (1 − 𝜋𝜋) is causal, and a fraction of SNPs 
(𝜋𝜋) is not: 




with probability 1 − 𝜋𝜋. 
After estimating π from the GWAS summary statistics of total sample, we used the mean 𝜒𝜒2 
statistics of all SNPs from the total GWAS to infer the mean 𝜒𝜒2 statistics of only the associated 
SNPs from the following relationship: 
1 ∗ 𝜋𝜋 + 𝜒𝜒2���𝑠𝑠𝑠𝑠𝑠𝑠𝑜𝑜𝑖𝑖𝑖𝑖𝑠𝑠𝑠𝑠𝑖𝑖𝑠𝑠 ∗ (1 − 𝜋𝜋) = 𝜒𝜒2���𝑠𝑠𝑅𝑅𝑅𝑅 𝑆𝑆𝑆𝑆𝑆𝑆𝑠𝑠, 
where we use the fact that the mean 𝜒𝜒2 statistics of the null SNPs is 1. Then, conditioning on the 
fraction of total sample size used for replication, we obtain an estimate of mean 𝜒𝜒2 statistics that 
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we would have gotten from the discovery GWAS, 𝜒𝜒2���𝐷𝐷𝑖𝑖𝑠𝑠𝑖𝑖𝑜𝑜𝑜𝑜𝑖𝑖𝑠𝑠𝑠𝑠, by scaling 𝜒𝜒2���𝑠𝑠𝑠𝑠𝑠𝑠𝑜𝑜𝑖𝑖𝑖𝑖𝑠𝑠𝑠𝑠𝑖𝑖𝑠𝑠 − 1 by 
the fraction of total sample size used for discovery. Lastly, we approximate the variance of the 
causal SNPs (𝜏𝜏2) by 
𝜒𝜒2����𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷−1
𝑆𝑆𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷
. The rest of our simulations proceed in the same manner as 
those used for calculating the expected replication record. We vary the fractions of total sample 
size used for replication from 5% to 40% in 5 percentage-point increments and repeat the 
simulation 10,000 times for each replication fraction. The optimal fraction of replication sample 
is determined as the fraction that maximizes the expected number of SNPs that are significant at 
the 5% level with Bonferroni correction in the replication sample. The Bonferroni-corrected P 
value threshold is determined as 0.05 divided by the number of genome-wide significant SNPs in 
simulated discovery GWAS at each iteration of the simulations. 
Our simulation results indicate that the optimal replication sample fractions are 30%, 25%, 25% 
and 20% for FAT, PROTEIN, SUGAR and CARBOHYDRATE, respectively, whereas the actual split as 
we had planned (i.e., UKB for discovery and all other cohorts for replication) corresponds to 
33%, 33%, 33% and 26%, respectively. When we compare the expected numbers of SNPs that 
are significant at the Bonferroni-corrected 5% level under the optimal and actual splits, they are 
0.37 and 0.32 (for FAT), 0.37 and 0.33 (for PROTEIN), 0.18 and 0.18 (for SUGAR) and 1.50 and 
1.46 (for CARBOHYDRATE). Though the expected numbers are slightly lower under the actual 
split, the differences are very small and all within the magnitude of 0.01. The simulation results 
provide evidence that our loss in statistical power due to our choice of how to split cohorts into 
discovery and replication samples is minimal. 
4.3 Replication of DRAM1 variant rs77694286 
A previous GWAS of macronutrient intake performed by Merino et al.69 identified a rare variant 
in DRAM1 (rs77692486, MAF1000GEUR = 0.01). However, this SNP only reached genome-wide 
significance (for PROTEIN) in their discovery phase, with the effect allele having a discordant sign 
(with P = 0.16) in their UKB replication phase. Here, we report the replication record for this 
SNP in our own meta-analyses. The sample overlap between our GWAS and Merino et al.’s 
GWAS is described in Supplementary Table 4.3. It is impossible to estimate the exact extent of 
overlap, because even for the same cohorts the sample sizes differed – likely because of 
expanded genotyping efforts and/or differences in QC protocols. The overlapping cohorts for the 
rs77694286 analysis are Fenland; RS; and UKB. Merino et al. also used EPIC-Norfolk data. 
Since EPIC-Norfolk participants overlap with EPIC-InterAct, there is also possible partial 
overlap there (EPIC-InterAct is one of our included cohorts). The estimated maximum sample 
overlap between Merino et al.’s non-UKB cohorts and our non-UKB cohorts for rs77694286 is N 
= 28,927 (EPIC-InterAct, Fenland, and RS) / N = 123,659 (Merino et al.’s non-UKB cohorts) = 
22.9%. Despite this overlap, rs77694286 does not come even close to genome-wide significance, 
as detailed below. In our own meta-analysis, we removed rs77692486 from most individual 
cohorts during individual cohort quality control (QC), mostly because it has a too low MAF 
according to our sample-size-specific MAF criteria. Prior to QC, the SNP is available in 12 
cohorts, with valid and non-missing summary statistics in all 12. Here, we meta-analyze the 
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SNPs across these cohorts for PROTEIN, and additionally across all cohorts minus UKB, since the 
effect was non-significant in UKB in the Merino et al. analysis. The results are displayed in 
Supplementary Table 4.3. We also calculate the corresponding (semi-standardized) effect sizes 
from Merino et al., and display them in the same table for comparison. In our meta-analysis that 
includes UKB (N = 212,527), the SNP does not nearly reach genome-wide statistical significance  
and the effect size was discordant (semi-standardized ?̂?𝛽 = −0.028 for allele G, P = 0.271) with 
respect to the effect size discovered by Merino et al. (semi-standardized ?̂?𝛽 = 0.121 for allele G, 
P = 1.9 × 10-9). In the meta-analysis that excludes UKB, the effect is concordant with respect to 
Merino et al. (semi-standardized ?̂?𝛽 = 0.028 for allele G, P = 0.560; Merino et al. semi-
standardized ?̂?𝛽 = 0.054 for allele G, P = 7.5 × 10-5) but indistinguishable from zero.  
We conclude that the rare variant rs77692486 does not currently appear to be a robust 
association for relative protein intake. Other independent large samples are needed to further 
study this association. Our results strengthen the notion that the interpretation of rare variant 
associations for complex traits with relatively small GWAS sample sizes requires extra caution. 
5 GWAS results from the combined meta-analyses 
5.1 LD Score regression intercept test for population stratification bias 
An important concern in GWAS studies is the potential confounding bias in SNP effects 
resulting from uncorrected-for population stratification. Population stratification refers to 
differences in genetic ancestry among participants included in the study. When differences in 
genetic ancestry (and thus, SNP allele frequencies) correlate with phenotypic differences, GWAS 
estimates can be biased. A salient example is a hypothetical study on chopstick use in a 
population that includes both East Asian and non-East Asian participants70. This study will find 
spurious associations for SNPs that differ in allele frequency between the East Asian and non-
East Asian participants, which could then be wrongly identified as “chopsticks genes”.  
Although we only include individuals of European ancestry in the current study, subtle 
differences between the different included European populations might still bias SNP effects, 
resulting in an overall inflation of the genome-wide SNP test statistics. To counteract this 
problem, all included cohorts added at least 5 principal components of the genetic relatedness 
matrix as covariates in their GWAS. However, this might not be completely effective. To 
estimate the inflation of genome-wide SNP statistics caused by remaining population 
stratification, we compare the intercepts obtained from LD Score regression67 to the mean 𝜒𝜒2 
statistics. (At the meta-analysis stage, we also use these intercepts to deflate the SNP test 
statistics; for details see Supplementary Information 3.4) The ratio 𝐼𝐼𝑛𝑛𝑠𝑠𝑖𝑖𝑠𝑠𝑖𝑖𝑖𝑖𝑖𝑖𝑠𝑠−1
𝛸𝛸2����−1
 describes the 
share of the inflation in the mean 𝜒𝜒2-statistic (𝛸𝛸2����) that is due to population stratification.  
We find that the intercepts from the LD Score regressions (performed for the meta-analyzed 
results of all cohorts) are close to unity (all < 1.009, Supplementary Table 5.1), indicating that 
the results of our GWAS are not likely influenced by issues related to population stratification. 
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When comparing these intercepts to the mean 𝜒𝜒2-statistics, we find that the share of inflation in 
the mean 𝜒𝜒2 that can be explained by population stratification is 5.63% (SE = 3.9%) for FAT, 
2.6% (SE = 4.6%) for PROTEIN, 1.6% (SE = 3.4%) for SUGAR, and 3.69% (SE = 3.0%) for 
CARBOHYDRATE. Note that none of these estimates can be statistically distinguished from 0%. 
These results indicate that the contribution of population stratification to the inflation of GWAS 
test statistics is likely to be small. This in turn suggests that a true polygenic signal is likely to be 
the main driver of the observed inflation of the chi-square statistics. 
5.2 Summary of the GWAS findings 
In the GWAS of the four dietary intake phenotypes, we detect 36 genome-wide significant loci: 
six independent loci for FAT; seven independent loci for PROTEIN; 10 independent loci for SUGAR; 
and 13 independent loci for CARBOHYDRATE (Main Table 1 and Supplementary Table 5.2). We 
list the imputation quality of SNPs that reach genome-wide significance across cohorts in 
Supplementary Table 5.3. Several of these loci overlap across phenotypes – in some cases, 
even the lead SNP itself is identical across phenotypes (Supplementary Table 5.4). After taking 
this overlap into account, we identify 21 loci that are independently associated loci across 
phenotypes. These 21 loci include two loci harboring independent lead SNPs (r2 < 0.1) that are in 
close vicinity (distance ≈ 1 Mb). 
The SNP effect sizes range from 0.015 to 0.098 phenotypic standard deviations per effect allele, 
and the explained phenotypic variance (incremental R2, i.e., coefficient of determination) ranges 
from 0.011% to 0.054%. The explained phenotypic variances for the top 50 independent lead 
SNPs for each of our four phenotypes are displayed in Extended Data Figure 5, where they are 
compared to the top 50 independent lead SNPs from other phenotypes (years of education, body 
mass index, waist-hip ratio adjusted for BMI, and height). Note that these sets of lead SNPs are 
phenotype-specific (i.e., not the same set of 50 SNPs across phenotypes). Here, we see that the 
explained variances for the diet composition lead SNPs are generally lower than those for BMI 
and height, slightly smaller than those for waist-hip ratio, and most comparable to those for years 
of education. (We note that effect sizes of SNPs do not necessarily scale with biological 
relevance. For instance, beneficial hypercholesteremia and schizophrenia drugs target genes 
whose common genetic variants have small effect sizes71,72. Small effect sizes are not 
unexpected, as most mutations with large effect sizes tend to be filtered out by evolutionary 
processes73. For dietary intake, knockout mouse studies of FGF21 show a marked effect on sugar 
intake48,49, although the GWAS effect sizes in humans are rather small in this locus. Hence, 
drugs that target FGF21 (which are currently on trial for obesity and type 2 diabetes74) could 
have a substantial effect on sugar intake, even though GWAS effect sizes are small.) 
We now highlight some notable specific findings (ordered according to chromosome and 
genomic location): 
(1) The lead SNP for PROTEIN located intronically in GCKR is in very high LD with a GCKR 
missense variant (r2 = 0.935) that is strongly associated with blood glucose levels75,76, 
triglycerides, cholesterol77–82, and type 2 diabetes83. GCKR codes for glucokinase regulatory 
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protein, which is in a family of enzymes vital for carbohydrate metabolism. It is unclear why it is 
associated with protein intake only. Since the GCKR lead SNP does not even reach (suggestive) 
significance for the other macronutrients (Supplementary Table 5.4), it seems unlikely that the 
association between protein and GCKR is driven by a protein—carbohydrate/fat/sugar 
substitution effect. Future research is therefore needed to study GCKR’s possible role in protein 
taste-preference or protein metabolism. 
(2) We identify an intronic variant in KLB (located on chromosome 4, associated with PROTEIN), 
which codes for klotho beta, and interacts with FGF21 (located on chromosome 19), the sweet 
and alcohol taste preference gene84. KLB SNPs were already identified for diet composition in 
previous GWAS11,12. FGF21 function depends on the availability of KLB; KLB acts as an 
essential co-receptor to FGF2185,86. Recent research into the effects of FGF21 function used 
brain-region-specific deletions of KLB to gain insight into the FGF21 tissues of action49. KLB 
has also been associated with alcohol consumption in previous GWAS87. Interestingly, the lead 
SNP was only associated with PROTEIN in our study, with P values > 10-5 for the other three diet 
composition phenotypes. In addition, MAGMA analyses point to another gene that interacts with 
FGF21: MLXIPL, which codes for a protein also known as Carbohydrate Response Element 
Binding Protein (chREBP) and is associated with FAT (Supplementary Table 5.6). MLXIPL 
acts as a transcription factor to FGF21. FGF21, KLB, and MLXIPL are located on different 
chromosomes (19, 4, and 7, respectively). Our results may imply that different genes of the same 
biological pathway might regulate different macronutrient preferences. 
(3) The polymorphic missense variant in ADH1B, which codes for the alcohol dehydrogenase 1B 
enzyme (MAF = 0.029), is associated with FAT. The T-allele of this variant decreases the 
enzyme’s ability to metabolize alcohol. The direction of effect is discordant; the allele that is 
associated with increased dietary fat intake is associated with a decreased conversion rate of 
alcohol into acetaldehyde, thereby increasing alcohol “sensitivity” and limiting an individual’s 
capacity to consume alcohol. ADH1B also has the capacity to metabolize lipid products such as 
hydroxysteroids (e.g., cholesterol) and lipid peroxidation products, which might also explain its 
link to dietary FAT intake. Accordingly, ADH1B is not only highly expressed in the liver, but also 
in adipose tissues (subcutaneous and visceral, and in the breast) according to the GTEx88 v7 
portal. We find that the association between ADH1B and FAT virtually disappears in a sample of 
UKB individuals (N = 79,192, Supplementary Table 5.7) who reportedly do not consume 
alcohol. That is, the SNP P value reduces to P = 0.037, the semi-standardized beta decreases 
from 0.118 (95% CI [0.097, 0.139]) in the full UKB to 0.044 (95% CI [0.003, 0.086]) in the 
sample of alcohol abstainers. This implies that individuals who derive relatively more energy 
from alcohol derive relatively less energy from fat, which may be a consequence of our 
phenotype construction (see Supplementary Information 2.8 for detailed explanation). In 
Supplementary Information 11.2.3, we also explore the possibility that the diets of former 
drinkers differ in composition from current or never drinkers, after taking calories from alcohol 
into account. 
(4) An intergenic variant located between CYP1A1 and CYP1A (MAF = 0.26) is associated with 
CARBOHYDRATE intake. These two genes, which are exclusively expressed in the liver according 
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to GTEx88 v7 portal, are involved in caffeine metabolism89,90. The largest GWAS of coffee 
consumption to date also identified our CARBOHYDRATE lead SNP in this locus as its top 
association90. The T-allele of this variant is associated with decreased caffeine consumption. 
With respect to CARBOHYDRATE, the effect is discordant, implying that the allele that is 
associated with increased dietary carbohydrate intake is associated with decreased caffeine 
metabolism and consumption. While this finding might imply a biological role for CYP1A genes 
in carbohydrate metabolism, the results might also hint at shared lifestyle choices pertaining to 
food and caffeinated drinks. 
(5) Two independent loci (tagging lead SNPs r2 < 0.1) located in the middle of a large 
polymorphic inversion region on chromosome 8, for which the estimated breakpoints are 
7,897,515 – 11,787,03263,91 (GRch37), are associated with all four macronutrients. The base-pair 
locations for the four lead SNPs in this region are 9,173,209 (rs7012637); 9,173,358 
(rs7012814); 9,183,358 (rs9987289) and 9,187,242 (rs1461729), and all are mapped to intronic 
regions of the same long, non-coding RNA (lincRNA) gene (AC022784.6), of which the 
biological function is unknown. However, a database of lincRNA genes indicates that this 
particular gene is highly constrained throughout evolution, with mutations in this site likely 
being deleterious69.  
The four lead SNPs in this locus (or SNPs in high LD with them; see Supplementary 
Information 6.2.1) have previously been associated with several blood phenotypes, including 
levels of cholesterol79,92 and levels of glucose in pregnant women75. The true LD estimates in 
such a complex inversion region may be difficult to estimate93, making it hard to conclude that 
this region actually carries two independently associated (and hence, potentially independently 
causal) variants for dietary intake. Other variants in this inversion region (which are not in LD 
with our lead SNPs) have previously been associated with neuroticism63. 
(6) We identify four variants in the intronic regions of FTO that are associated respectively with 
FAT, PROTEIN, SUGAR, and CARBOHYDRATE; each phenotype has its own individual lead SNP, all 
of which are in high LD with each other (r2 > 0.92, MAF > 0.40. FTO is strongly associated with 
body mass index (BMI) and related anthropometric phenotypes94,95, as well as type 2 diabetes96, 
age at menarche97, and breast cancer98. The causal BMI gene in the genomic region appears to be 
IRX3, which is regulated by variants in FTO99,100. A previous dietary intake GWAS has already 
identified GWAS hits in the FTO region11. With respect to BMI, the effects are concordant for 
FAT and PROTEIN, and discordant for SUGAR and CARBOHYDRATE, implying that the allele that 
increases BMI is associated with increased dietary fat and protein consumption, and decreased 
dietary sugar and carbohydrate consumption. These directions mirror the overall genetic 
correlations between BMI and dietary intake (Supplementary Information 10). 
(7) We identify a genomic locus associated with CARBOHYDRATE that is located near a well-
known large inversion polymorphism on chromosome 17101, which notably includes the genes 
MAPT (microtubule-associated protein tau) and CRHR1 (corticotropin releasing hormone 
receptor 1). MAPT is known to be involved in neurodegenerative disorders such as 
frontotemporal dementia, Alzheimer’s disease and Parkinson’s disease (disorders sometimes 
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summarized under the term “tauopathies”102–105). CRHR1 may affect corticosteroid response in 
asthma patients106,107. The inversion polymorphism has also been associated with neuroticism63.  
(8) We identify a well-known polymorphic missense variant in APOE (MAF = 0.152) that is 
associated with FAT, SUGAR, and CARBOHYDRATE), which codes for apolipoprotein E, a protein 
that carries fatty acids through the bloodstream, and is involved in fatty acid metabolism. APOE 
is highly expressed in the liver and adrenals but also in the brain (it is the brain’s principal 
cholesterol carrier108), where it is associated with the neurodegenerative processes related to 
Alzheimer’s109,110 and Lewy body disease111. The C-allele of the APOE missense mutation 
strongly predisposes to cognitive decline and Alzheimer’s disease. We find that the effect is 
concordant with respect to SUGAR and CARBOHYDRATE and discordant with respect to FAT, 
implying that the allele that increases Alzheimer’s risk is associated with increased dietary sugar 
and carbohydrate consumption, and decreased dietary fat consumption. However, the effects of 
this variant are greatly reduced in a sample of UKB individuals aged younger than 60 (N = 
79,192), with P values > 0.01 and effect sizes generally only half as large (see Supplementary 
Table 5.7). This could imply that the APOE association is driven by a selection bias based on 
age (and therefore, Alzheimer’s risk or status) of participants, since dietary intake also correlates 
marginally with age at the phenotype level. However, the 95% CIs for the effect sizes still 
largely overlap, making it hard to conclude whether the APOE associations are biased or 
indicative of biological relevance. The overall genetic correlations between dietary intake and 
Alzheimer’s disease are small and non-significant, however (see Supplementary Table 10.2). 
(9) Several variants located in a region spanned by Chr. 19: 49.21 – 49.27 Mb, which harbors 
genes that have been associated with sweet and alcohol taste preference in experimental mice 
and monkey studies48,49. Previous GWAS of dietary macronutrient intake had already identified 
variants in this locus11,12. Here, we find two independent loci in the FGF21 gene, with additional 
lead SNPs in MAMSTR and IZUMO1. The two lead SNPs in FGF21 gene are independently 
associated according to our locus definition (r2 < 0.1, Supplementary Table 5.4). They are the 
SNPs rs838133, associated with FAT, PROTEIN, SUGAR and CARBOHYDRATE, and rs62132802, 
associated with SUGAR at genome wide significance, and with FAT, PROTEIN and CARBOHYDRATE 
at suggestive significance (with P < 4.7 × 10-7). Different genes in this locus (MAMSTR, 
IZUMO1 and FGF21) harbor three different lead SNPs associated with FAT, 
SUGAR/CARBOHYDRATE, and PROTEIN. However, these three lead SNPs reach genome-wide 
significance for all phenotypes and are all in relatively strong LD with each other (r2 = 0.803, 
0.617, and 0.763), which might imply that the different lead SNPs tag the same biological effect 
for all phenotypes, despite their differing locations across genes. Thus, any conclusions that 
MAMSTR is the causal gene for FAT, IZUMO1 is the causal gene for SUGAR/CARBOHYDRATE, and 
FGF21 is the causal gene for PROTEIN are not justified by our results. 
Seven of the remaining independently associated loci have not been associated with any other 
phenotypes in previously published and catalogued GWAS studies (Supplementary 
Information 5.5), and are located in or near genes that have not been studied in depth to date 
(these include the protein-coding genes CTNNA2, SNORD66, MAD1L1, and L3MBTL4). The 
other three loci have been associated with BMI, information processing speed, and alcohol 
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consumption (Supplementary Information 6). Across the 21 independently associated loci, 
seven lead SNPs are in (or when intergenic, nearest to) lincRNA genes that have no protein 
product and no published study on their biological function. 
5.3 MAGMA gene-based analysis 
We perform MAGMA gene-based analysis to assess the number of genes that reached “genome-
wide significance” based on our meta-analysis results, where the P value threshold to declare 
genome-wide significance here is based on the number of genes tested (rather than the number of 
independent SNPs tested). This greatly reduces the multiple testing burden and could reveal 
statistically associated genetic loci that do not harbor statistically significant SNPs due to 
insufficient statistical power.  
All the SNPs from our summary statistics that are located between the transcription start- and 
stop-sites of a gene annotated to that gene, based on NCBI 37.3.13 gene definitions. The 
implementation of this gene annotation is a limitation of MAGMA, as genes are also regulated 
by genetic variants that lie outside of the gene itself. MAGMA first calculates a per-gene test 
statistic (based on SNP summary statistic data) as the mean of the GWAS –log10 P values for all 
the SNPs between the transcription start and stop sites of a gene. MAGMA then calculates a P 
value for the resulting gene test statistic, using a procedure that takes into account LD between 
SNPs112. We use our main reference panel (described in Supplementary Information section 
3.3.1) for LD estimations. MAGMA does not correct for LD between genes, which can result in 
several genes in the same genomic locus reaching statistical significance because they are in LD 
with each other. Bonferroni correction is applied to account for multiple testing, counting each 
gene as an “independent” test. Since genes are often (partially) in LD with each other, this is a 
conservative correction for multiple testing. 
5.3.1 MAGMA results 
The results are reported in Supplementary Table 5.5 and Extended Figure 6. After Bonferroni 
correction, we discover 28 significant genes for FAT, 18 significant genes for PROTEIN, 27 
significant genes for SUGAR, and 41 significant genes for CARBOHYDRATE. After considering 
overlapping genes between the phenotypes, we can report 81 uniquely associated “MAGMA 
genes.”  
Curiously, all phenotypes have the exact same top two genes (located in the sweet taste 
preference locus on Chr. 19: 49 Mb): RASIP1, followed by MAMSTR. None of the lead SNPs for 
any of the diet composition phenotypes are located in RASIP1, but for all phenotypes, RASIP1 is 
by the far the most significant MAGMA-gene in this locus. We do not know if this is indicative 
of true biological relevance or merely a statistical artifact. Although MAGMA corrects for gene 
length, the test for RASIP1 is based on the larger number of SNPs, while FGF21 has the smallest 
number of SNPs; it may be that the effect of RASIP1 is simply measured with more precision. 
The sweet taste preference gene FGF21 is the 6th most strongly associated gene for FAT, the 3rd 
for PROTEIN, the 4th for SUGAR, and the 5th for CARBOHYDRATE. While three additional genes 
(FUT1, FUT2 and IZUMO1) in that locus are significant for all phenotypes, a seventh gene 
located there (NTN5) is only significant for FAT and SUGAR (and by far not associated with 
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PROTEIN and CARBOHYDRATE). Other significant genes in this locus are BCAT2 (for PROTEIN) 
and FAM83E and SPHK2 (for FAT).  
MAGMA also identifies genes in loci that do not (yet) have a GWAS hit for any of the four 
phenotypes. This means that none of these genes are near (>1 Mb) any of the GWAS lead SNPs.  
For FAT, MAGMA identifies eight new loci; for PROTEIN, four; for CARBOHYDRATE, 15; and for 
SUGAR, ten. Taking overlap between phenotypes into account, MAGMA identifies a total of 32 
new loci. A notable identified gene for dietary intake is MLXIPL, which codes for a protein that 
is known as Carbohydrate Response Element Binding Protein (chREBP). MAGMA identified 
this gene for FAT only. MLXIPL acts as a transcription factor to FGF21. FGF21, KLB, and 
MLXIPL are located on different chromosomes (19, 4, and 7, respectively), reflecting the fact 
that genes that interact with each other do not need to be located on the same chromosome. Our 
results may imply that different genes of the same pathway might regulate different 
macronutrient preferences. 
5.4 Overlap between loci 
As already noted in our summary of GWAS results (Supplementary Information 5.2), we find 
that several GWAS loci areassociated with more than one macronutrient. This is expected given 
the non-zero phenotypic and genetic correlations between macronutrients, as described above in 
Supplementary Information 7. In Supplementary Information 2.8, we also provide more 
context on the interpretation of these shared loci.  
In this section, we check all diet composition lead SNPs for association more than one 
macronutrient. The results are summarized in Supplementary Table 5.4, which displays the 
lead SNPs’ P values, effect sizes, and explained variances for all four macronutrients, as well as 
previous GWAS Catalog associations for SNPs in this locus. We also report the LD estimates 
(r2) for the independent lead SNPs that are located near each other (≈ 1 Mb).  
Among the 21 independently associated loci, we find that nine are represented by lead SNPs that 
are exclusively associated with one macronutrient, with none of the lead SNPs reaching 
suggestive significance (P > 1 × 10-5) for any other macronutrient. Six loci contain at least one 
lead SNP that reaches genome-wide significance for more than one (but not all four) 
macronutrients, while two loci contain at least one lead SNP that reaches genome-wide 
significance for all four phenotypes (notably, the loci characterized by FTO and FGF21, 
respectively). Four of the 21 loci’s lead SNPs only reach suggestive significance (P value < 10-5) 
for at least one additional macronutrient. 
Finally, we report the LD estimates for the two genomic loci that contain more than one 
independent lead SNP according to our r2 < 0.1 threshold. That is, we find two independent lead 
SNPs for CARBOHYDRATE in a locus spanned by Chr. 8: 9.17-18 Mb. These two independent lead 
SNPs (rs7012637 and rs9987289) are in very weak LD with each other (r2 = 0.074). The other 
set of closely colocated independent lead SNPs are associated with SUGAR and are found in a 
region spanned by Chr. 19: 49.21-27 Mb. These two lead SNPs (rs838144 and rs6213802) are 
also in very weak LD with each other (r2 = 0.078). However, we note that these two loci (on 
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chromosome 8 and 19) are located in two large inversion polymorphisms that are potentially 
characterized by complex (and hard to measure) LD patterns. Existence of the first 
polymorphism was confirmed previously63,113, whereas the chromosome 19 inversion 
polymorphism is based on preliminary and unpublished findings from the Estonian biobank 
(Esko and Gonzalez, unpublished work). This could imply that the “independent loci” found in 
these inversions are not actually independent and instead tag the same causal biological effect. 
5.5 Overlap with traits in the NHGRI-EBI GWAS catalog 
We assess if any of the lead SNPs and their “LD partners” (r2 > 0.6, see Supplementary 
Information 6.2.1) has been associated with any other trait by querying them in the NHGRI-EBI 
GWAS Catalog114 (https://www.ebi.ac.uk/gwas/, download date September 19, 2017). This is a 
database that catalogues and harmonizes information from SNP associations in published and 
peer-reviewed GWAS. Here, we only record SNP associations that reached genome-wide 
significance (P value < 5 × 10-8) in their original GWAS. While some of the findings were 
described in the summary of the GWAS (Supplementary Information 5.2 and Supplementary 
Table 5.4), the full results are displayed in Supplementary Table 5.6. We shortly summarize 
them below.  
5.5.1 Results 
For FAT, we find 255 overlaps in the GWAS catalog with 44 unique SNPs, representing five 
individual loci (where a locus is defined by its lead SNP). Only one FAT locus did not surface in 
the GWAS Catalog with its lead SNP or any of its LD partners. As noted earlier, we find 
overlaps with alcohol consumption (and alcohol consumption related cancers, as driven by the 
ADH1B association), obesity (and related anthropometric constructs and diseases, as driven by 
the FTO association), fibrinogen levels, Alzheimer’s disease and related brain-, blood-, and 
cognitive-phenotypes (as driven by the APOE association, which is also associated with body fat 
and diabetes), autoimmune diseases (especially inflammatory bowel disease), vitamin levels, and 
urinary and blood metabolite levels (as driven by the sweet taste preference associated FGF21 
locus). As mentioned earlier, we also find overlap with the two SNPs previously11,12 identified 
for dietary macronutrient intake. 
For PROTEIN, we find 274 overlaps in the GWAS Catalog with 43 unique SNPs, representing five 
individual loci. Two PROTEIN loci did not surface in the GWAS Catalog with its lead SNP or any 
of its LD partners. As noted earlier, we find overlaps with circulating lipids, C-reactive protein, 
lactate, uric acid, glucose, insulin, albumin, calcium, liver enzymes, and creatinine; blood cell 
phenotypes; inflammatory bowel disease; resting heart rate; gout; height; kidney disease; and 
waist circumference (driven by the GCKR associated locus and the chromosome 8 inversion 
polymorphism locus), alcohol consumption (driven by the KLB associated locus), obesity (and 
related anthropometric constructs and diseases, driven by the FTO locus), and urinary 
metabolites, homocysteine levels, and skin disease (as driven by the sweet taste preference 
associated FGF21 locus). As mentioned earlier, we also find overlap with the two SNPs 
previously identified for dietary macronutrient intake. 
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For SUGAR, we find in the GWAS Catalog 233 overlaps with 39 unique SNPs, which are driven 
by five individual loci. This means that five SUGAR loci did not appear in the GWAS Catalog. As 
noted earlier, we find overlap at obesity (and related anthropometric constructs and diseases, 
driven by the RARB locus and the FTO locus), Alzheimer’s disease and related brain-, blood-, 
and cognitive-phenotypes (as driven by the APOE association, which is also associated with 
body fat and diabetes). As mentioned earlier, we also find overlap with the two SNPs previously 
identified for dietary macronutrient intake. 
For CARBOHYDRATE, we find 302 overlaps with 70 unique SNPs, representing 10 individual loci. 
Three CARBOHYDRATE loci did not appear in the GWAS Catalog. Aside from associations with 
obesity (and related anthropometric constructs and diseases, driven by the RARB locus and the 
FTO locus) and Alzheimer’s disease and related brain-, blood-, and cognitive-phenotypes (as 
driven by the APOE association, which is also associated with body fat and diabetes), we find 
overlap at fibrinogen-, liver enzyme-, glucose-, C-reactive protein-, and lipid-levels (driven by 
the chromosome 8 inversion polymorphism locus), caffeine and coffee consumption and 
metabolism, and with Parkinson’s disease, intracranial volume, male pattern baldness, ovarian 
cancer, bone density, and blood cell phenotypes (driven by the chromosome 17 inversion 
polymorphism locus). As mentioned earlier, we also find overlap with the two SNPs previously 
identified for dietary macronutrient intake. 
5.5.2 Discussion 
This widespread overlap with diet composition and other (sometimes seemingly unrelated) traits 
could be caused by different scenarios. One scenario is pleiotropy, which means that a gene can 
be involved in different biological processes, causing the gene to be associated with different 
traits. Pleiotropic effects can depend, for instance, on the tissue in which the gene is expressed. It 
could also be caused by linkage between genes with disparate functions, where this linkage is 
merely causing a statistical (but not biologically causal) association between a trait and different 
genes in a genomic locus. Two traits may also overlap via mediation, with genetic variants 
affecting a trait (e.g., obesity susceptibility) having phenotypic downstream effects on another 
trait (e.g., cardiovascular disease). Finally, the overlap between two traits may be spurious, 
caused by a third, unmeasured trait that is associated with two overlapping traits. Note that 
genetic overlap at a small number of loci does not have to imply shared overall genetic 
architecture. This phenomenon was exemplified by two different autoimmune disorders that 
share several genome-wide significantly associated loci but a non-significant overall genetic 
correlation115. In this sense, the genetic correlations reported in Supplementary Table 10.2 may 
be more informative in assessing potential for shared etiology between traits. However, the trait 
associations for the individual loci can still be helpful in understanding potential individual gene 
functions.  
6 Biological annotation of GWAS findings 
In order to gain insight into the biological architecture of diet composition, we employ several 
different strategies. First, we annotate the “genome-wide” architecture of diet composition by 
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partitioning the genetic signal from our summary statistics into several different types of 
functional categories. This is achieved with stratified LD Score regression, which assesses from 
which functional categories the polygenic GWAS signal emerges. We assess three broad types of 
functional categories: 1) different genomic annotations from the “baseline model”; 2) tissue 
types as ascertained with chromatin (histone-mark) data; 3) tissue types as ascertained with 
specifically expressed genes in GTEx data. 
To annotate the top GWAS findings (both in terms of SNPs and in terms of genes), we perform 
MAGMA gene-based analysis, a hypothesis-free test that uses GWAS summary statistics to 
assess which protein-coding genes reach genome-wide significance. To understand the biological 
functions of the genes that were significant in any of the four diet composition phenotypes, we 
then query them in the Gene Network database, which assigns genes’ predicted functions on the 
basis of publicly available co-expression information.  
To annotate the lead GWAS SNPs, we query whether they (or any of their LD partners) are 
associated with gene expression in relevant GTEx tissues, or whether they are in LD with any 
SNPs that have protein-altering consequences. 
6.1 LD Score partitioning of heritability 
6.1.1 General method 
We examine the enrichment of functional genomic annotations of our GWAS results by 
partitioning our phenotypes’ polygenic signals into different functional categories. These 
annotations describe in which tissue or cell type diet composition SNPs are likely to be 
expressed, or in which genomic classes the diet composition SNPs are likely to fall (e.g., exonic 
or intronic, promoter or enhancer regions, evolutionarily conserved regions, etc.). We do so 
using stratified LD Score regression116, which is based on the following moment condition: 
𝐸𝐸�χ𝑗𝑗2� = 𝑆𝑆�𝜏𝜏𝑖𝑖𝑡𝑡(𝑗𝑗, 𝑐𝑐)
𝐶𝐶
𝑖𝑖=1
+ 𝑆𝑆𝑖𝑖 + 1, 
where 𝜒𝜒𝑗𝑗2 is the chi-square statistic for SNP 𝑗𝑗 from a GWAS, 𝑆𝑆 is the sample size of the GWAS, 
𝑐𝑐 indexes functional categories that are not necessarily disjoint, 𝑡𝑡(𝑗𝑗, 𝑐𝑐) is the stratified LD Score 
of SNP 𝑗𝑗 with respect to functional category 𝑐𝑐, 𝜏𝜏𝑖𝑖 is the average contribution to heritability of a 
SNP due to its membership in category 𝑐𝑐, and 𝑖𝑖 is a term that measures confounding biases such 
as population stratification. 
Finucane et al.116 proved that under a set of assumptions, the explained proportion of heritability 
per functional category can be estimated with a regression analogous to the equation above. 
Enrichment for a particular functional category is then defined as the fraction of heritability due 
to that category, divided by the fraction of SNPs in the category. However, the heritability due to 
SNPs in the category is simply the sum of their squared effects. Since SNPs may belong to more 
than one functional category, enrichment for a particular category may be driven by overlapping 
enrichment at another category. In this analysis, we therefore rely more strongly on the statistical 
significance of the regression coefficients (𝜏𝜏𝑖𝑖) from the stratified regression analysis, as these 
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coefficients are corrected for the “baseline model” described below. Note that the tissue 
categories (both those based on chromatin data and GTEx gene expression data) are also only 
corrected for the baseline model, meaning that significance of the regression coefficients can 
therefore still be driven by signal coming from overlapping tissues. 
We conduct separate analyses, using three difference sets of reference data. First, we used the 
Finucane et al.116 “baseline model” that involves 24 main functional annotations of interest, plus 
a number of ancillary annotations formed by extending 500-kb windows around SNPs that 
qualify for the main annotations. These windows are included to control for spurious association 
caused by SNPs flanking the functional annotations. This results in a total of 52 tissue 
annotations. The baseline model includes annotations such as different histone modifications; 
promotor or enhancer regions; transcription start sites; repressed regions; 3’ and 5’ UTR regions; 
DNAse hypersensitive sites; protein coding regions; intronic regions;  evolutionarily conserved 
regions (which captures genomic regions that are observed in 29 different mammal species117); 
and more. Several of these annotations are defined more than once by means of different 
reference data sources. 
We then perform two separate analyses, which used tissue-level annotations that were based, 
respectively, on i) histone-mark demarcations (henceforth referred to as “chromatin data”)116 and 
ii) gene expression data from the Genotype-Tissue-Expression (GTEx) Project88,118. The 
chromatin annotations from Finucane et al.116 are based on ChIP-seq data, which ascertains 
whether SNPs are located in or near histone marks that are associated with increased gene 
expression. Finucane et al.116 grouped several tissues and cell types into 10 broad tissue types: 
Adrenal/Pancreas, Cardiovascular, Central Nervous System, Connective/Bone, Gastrointestinal, 
Immune, Kidney, Liver, Skeletal Muscle, and Other.  
The GTEx-based annotations provided by Finucane et al.118 span 53 tissues. Finucane et al. 
named this new implementation of partitioned LD Score regression “LDSC-SEG”, short for “LD 
Score regression applied to specifically-expressed genes.” To this end, they identified sets of 
genes that are specifically expressed in the individual tissues. SNPs located in one of these genes 
or within 100 kb of either endpoint were assigned the tissue-level annotation. These tissue 
annotations based on GTEx are far more specific than the annotations based on chromatin data 
since, for example, they split the brain into 15 different tissue types, whereas the chromatin data 
only designates a broad “Central Nervous System” term.  
For both the chromatin and GTEx tissue analyses, we also include the baseline annotations as 
control covariates. As a reference panel for calculating LD scores, we use European-ancestry 
samples in the 1000 Genomes Project and conducted the analysis on HapMap3 SNPs. We 
address the autocorrelation and heteroscedasticity issues inherent in running regressions using 
LD Scores by weighting the regression with LD Scores. We follow the recommendation of 




LD Score partitioning of heritability according to functional genomic categories 
The results are displayed in Supplementary Table 6.1). For all of our four phenotypes, the 
baseline annotation “Conserved” is the only annotation that has  𝜏𝜏𝑖𝑖 that is distinguishable from 
zero after Bonferroni correction, with a corresponding 25.5-fold (SE = 4.4) enrichment factor for 
FAT, 19.8-fold (SE = 4.4) enrichment factor for PROTEIN (SE = 4.4), 26.3-fold (SE = 3.7) 
enrichment factor for SUGAR and 25.2-fold (SE = 3.4) enrichment factor for CARBOHYDRATE. All 
these enrichment factors are distinguishable from zero. They correspond to explaining 66.5% (SE 
= 11.5%) of heritability for FAT, 51.6% (SE = 11.6%) for PROTEIN, 38.7% (SE = 9.7%) for SUGAR 
and 65.7% (SE = 8.8%) for CARBOHYDRATE. 
LD Score partitioning of heritability according to 10 chromatin-demarcated tissues 
For all our phenotypes, the coefficient for “Central Nervous System” category is distinguishable 
from zero, with enrichment factors of 2.97 (SE = 0.53) for FAT, 3.67 (SE = 0.51) for PROTEIN, 
2.96 (SE = 0.46) for SUGAR, and 3.21 (SE = 0.39) for CARBOHYDRATE (Supplementary Table 
6.2). This corresponds to explaining 44.1% (SE = 7.9%) of the heritability for FAT, 54.6% (SE = 
7.5%) for protein, 44.1% (SE = 6.8%) for SUGAR, and 47.7% (5.8%) for CARBOHYDRATE. Only 
one other tissue-level partition is enriched in any of our four phenotypes: for FAT, 
“Adrenal/Pancreas” has a significant regression coefficient, with a 3.98 (SE = 0.71) enrichment 
factor, representing 37.3% (SE = 6.7%) of explained heritability for FAT. 
LD Score partitioning of heritability according to 53 GTEx tissues 
All functional categories with regression coefficients that are distinguishable from zero in the 
LDSC-SEG analyses are brain regions, with FAT having the most enriched regions in 10 brain 
regions, while CARBOHYDRATE had the fewest at zero, whereas brain tissues only reached 
marginal significance after Bonferroni correction (Supplementary Table 6.3). For FAT we find 
significance for the amygdala, anterior cingulate cortex, caudate, cortex, frontal cortex, 
hippocampus, hypothalamus, nucleus accumbens, putamen (basal ganglia), and substantia nigra. 
Interestingly, PROTEIN also shows significance for the hypothalamus and substantia nigra but is 
significant in two regions where FAT is not: cerebellum and cerebellar hemisphere. SUGAR shows 
significance for the amygdala, anterior cingulate cortex, cortex and frontal cortex.  
6.1.3 Discussion 
First, we find that evolutionarily “conserved regions” (across 29 mammal species117) is the only 
significant genomic annotation in the baseline model. While this could hint at evolutionary 
selection for dietary behavior, we note that the “conserved” category was the most significantly 
enriched annotation across a range of health and behavioral phenotypes in Finucane et al.116, 
indicating that mutations in evolutionarily conserved regions affect a wide variety of phenotypes. 
As for the tissue categories, we find the most consistent evidence for involvement of the brain, as 
seen in both the chromatin and GTEx analyses. While the chromatin data also indicated a role for 
Adrenal/Pancreas for FAT, this was not replicated with the GTEx data. This could mean that the 
Adrenal/Pancreas tissues are too broadly defined in the chromatin data (or overlap too much with 
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SNPs annotated to other regions), or that the GTEx data are underpowered to capture specifically 
expressed genes in adrenal or pancreatic regions. 
With regards to the brain tissues, we find that each diet composition phenotype seems to have its 
own pattern of associated brain regions. The exception is CARBOHYDRATE, for which we find no 
specific brain region enrichment after Bonferroni correction, although the chromatin data do 
indicate a role for the central nervous system. We anticipate that specific brain tissues will start 
reaching significance with larger GWAS sample sizes. For FAT, PROTEIN and SUGAR, the 
confidence intervals of the effect sizes largely overlap, hampering conclusions on the specificity 
of involved brain regions. The brain-region-specific results are also hard to interpret due to 
probable overlap in gene expression across brain regions. For this reason, LDSC-SEG also offers 
reference files for the 14 brain regions, where sets of specifically-expressed genes were 
ascertained by comparing brain regions to each other – as opposed to comparing brain regions to 
the rest of the bodily tissues. However, we are underpowered to perform these analyses. GTEx 
does not cover all parts of the brain (with regions in the parietal, occipital and temporal lobes 
largely missing) and is based on small donor sample sizes, stressing the need for replication of 
these findings in independent samples. Finally, we stress that the LDSC-SEG analyses only 
found significant involvement of brain regions and no other bodily tissues (even before 
Bonferroni correction). Together, these analyses highlight the importance of the brain for 
macronutrient intake. 
6.2 Annotation of genome-wide significant genes and loci 
To gain insight into the biological architecture of the genome-wide significant loci, we query the 
lead SNPs and their LD partners in several databases: 1) in Haploreg v4119,120, which displays 
dbSNP information for SNPs’ protein-coding status; 2) in the GTEx eQTL database v6p88,121, 
which records whether SNPs are associated with expression of any measured gene transcript in 
53 different tissues. We also query the lead SNPs and their LD partners in the NHGRI GWAS 
Catalog, as described in Supplementary Information 5.5. Finally, we apply MAGMA gene-
based analysis, which tests the GWAS summary statistics for significance of 18,224 protein-
coding genes, greatly reducing the multiple-testing burden compared to GWAS of individual 
SNPs. We then query the significant “MAGMA-genes” from that analysis in the Gene 
Network122 database, which predicts gene functions on the basis of co-expression patterns and 
summarize the most frequently occurring predicted functions. 
6.2.1 Definition of LD partners 
In accordance with previous SSGAC projects63,64,91, we create a list of “LD partners” for each 
phenotype’s lead SNPs. It is important to consider these LD partners and not just the lead SNPs 
themselves, because the lead SNPs are not necessarily the causal variant in the locus, and the 
lead SNPs may not be present in the GTEx database or studies included in the GWAS Catalog 
(while some of their LD partners might be). Thus, the SNPs in high LD with the lead SNP may 
tag or represent biologically relevant effects. 
Here, we define LD partners as SNPs that are in high LD with the lead SNP. This contrasts with 
the locus definition we used for the determination of independent lead SNPs in Supplementary 
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Information 3.3.4, which uses a relatively low r2 threshold (r2 > 0.1). This is necessary, as SNPs 
weakly correlated with the lead SNP may only be significant because of this correlation and not 
because they tag an independent biological effect. This might especially be an issue in larger 
GWAS sample sizes. Thus, for the annotation of the biological functions of lead loci, we do not 
consider such weakly correlated SNPs, as they are unlikely to capture biological effects that are 
relevant for diet composition. We therefore define the lead SNPs’ LD partners as being in at least 
moderate LD with the lead SNP (r2 > 0.6) and located less than 250 kb from the lead SNP (both 
upstream and downstream, representing a 500-kb window around lead SNP). We perform these 
LD calculations in our main reference panel described in Supplementary Information 3.3.1. 
6.2.2 dbSNP protein-altering status 
We query all diet composition lead SNPs and their LD partners in HaploReg v4119,120 
(downloaded June 7, 2016), a database that displays dbSNP protein-coding status of SNPs. 
Protein-altering (“nonsynonymous”) SNPs are SNPs that change the amino acid (and therefore, 
protein) composition of a gene product. HaploReg defines four different protein-altering 
categories: “missense,” representing a mutation which results in a different amino acid being 
coded; “nonsense,” representing a mutation which results in a stop-codon being coded, marking 
an abrupt end in the gene product (these variants are also known as “truncating” variants); 
“frameshift,” representing a mutation that changes the reading frame of a gene, resulting in the 
codons being translated in a completely different way; and “splice site donors” and “splice site 
acceptors,” representing mutations that change the way a gene is spliced. The latter three variant 
classes are sometimes referred to as “loss of function” variants123, as they can have severe 
consequences on gene functionality. 
The results are displayed in Supplementary Table 6.4. We find 34 unique protein-altering 
variants in LD with the lead SNPs (in two cases, the lead SNP itself is the protein-altering 
variant). Among these, 32 variants were missense, and 2 variants re nonsense. Notable variants 
are (as described earlier in Supplementary Information 5.2) the well-known missense 
mutations in APOE, ADH1B, MAPT, and GCKR. In the sweet- taste preference locus on Chr 19: 
49 Mb, we find that the lead SNPs for all four phenotypes are in LD with a missense mutation in 
RASIP1 (a gene involved in vasculo- and angiogenesis according to Gene Ontology), while 
PROTEIN, SUGAR and FAT are in LD with a missense variant in IZUMO1 (an essential gene for 
sperm-egg fusion124), and FAT is in LD with a nonsense and a missense variant in FUT2 (a gene 
involved in sugar metabolism that protects against viral infection125–127 and is associated with gut 
microbiome composition128).  
On Chr. 17: 43 Mb, the lead SNP for CARBOHYDRATE is in LD with missense variants in MAPT 
(a gene associated with Alzheimer’s disease, where seven distinct missense variants are in LD 
with the lead SNP) as well as with STH, KANSL1 (a gene involved in the regulation of gene 
expression), SPPL2C (a gene almost exclusively expressed in the testis), and a nonsense variant 
in CRHR1 (i.e., corticotropin releasing hormone receptor 1, an essential regulator for cortisol 
homeostasis; among other physiological effects, cortisol is a hormone that is essential in the 
stress-induced “fight or flight” system, where it enhances glucose availability in the 
bloodstream).Finally, we find two missense mutations in LD with the lead SNP for 
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CARBOHYDRATE. Both are in CCDC171, a gene involved in regulation of gene expression 
according to Gene Ontology. 
6.2.3 GTEx gene expression eQTLs 
In this section, we report whether any of our lead SNPs (or their LD partners) are associated with 
gene (transcript) expression in the GTEx (Genotype-Tissue expression) portal88. A SNP that is 
associated with gene (transcript) expression is called an “expression quantitative trait locus” 
(eQTL). We do this to gain insight into the potential functional consequences of these SNPs. 
Gene expression is important since the vast majority of GWAS lead SNPs for human complex 
traits lie in non-coding regions129. Thus, most SNPs important for human health and behavior are 
likely to exert their effect via altered gene expression rather than altered protein composition. 
The publicly available data from the GTEx project are based on RNA-sequencing results from 53 
different human tissues and cell types from postmortem donors. By using RNA-sequencing, 
GTEx could measure RNA levels of protein-coding genes, as well as RNA levels that are only 
involved in regulation of gene expression (e.g., RNA transcripts encoded by long noncoding 
RNA genes). In order to establish statistically significant eQTLs (i.e., expression quantitative 
trait loci, which are SNPs statistically associated with transcript expression) in these tissues, 
GTEx performed an elaborate two-step false discovery rate correction88. Here, we report only 
eQTLs (for the lead SNPs and their LD partners) that were significant at P < 0.05 after this false 
discovery correction. We downloaded the GTEx v6 eQTL data on December 13, 2016. 
Prior to examining our GWAS results, we selected a number of tissues we deemed of a priori 
relevance for diet composition. These are: all adipose tissue, adrenal gland, all nervous (i.e., 
brain, pituitary, and tibial) tissue, all colon and intestinal tissue, liver, skeletal muscle, pancreas, 
stomach, thyroid, and whole blood. The donor sample sizes for these tissues ranged from N = 72 
(for anterior cingulate) to N = 361 (for skeletal muscle). Note that these sample sizes are rather 
small, implying relatively low statistical power for discovery of all relevant eQTLs. After 
performing the stratified LD Score regression for our GWAS results, however, which relied on 
epigenetic histone mark data, we only find strong ex post evidence for enrichment of brain- and 
possibly adrenal/pancreas tissue (Supplementary Information 6.1), so we mainly focus our 
written summary of eQTL findings here on the pancreas tissue and the tissues of the central 
nervous system. The eQTL findings for the other tissues described above (e.g., skeletal muscle, 
adipose, etc.) can still be found in Supplementary Table 6.5. 
The results are displayed in Supplementary Table 6.5. We found a total of 62 unique “eQTL 
genes” across the four phenotypes and across all included tissues. These “eQTL genes” are 
unique transcripts that were associated with our lead SNPs or SNPs in strong LD with them. 
These included 37 eQTL genes that could be mapped to genes with existing gene symbols, 
indicating that these are genes with known gene products. If we consider the same eQTL gene 
(i.e., gene-SNP pairing) occurring in two different tissues as two separate eQTLs genes, we find 
381 eQTL genes, of which 244 have defined gene symbols. 
FAT. Across all tissues, we find a total of 20 eQTLs for FAT, representing nine unique eQTL 
genes, with six of those having gene symbols. Two of the eQTLs are in brain tissues, and one 
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eQTL is in adrenal tissue. The eQTLs are driven by three loci: the diabetes locus on Chr. 7: 1 
Mb, the cholesterol locus on Chr. 8: 9 Mb, and the sweet taste preference locus on Chr. 19: 49 
Mb. 
PROTEIN. Across all included tissues, we find a total of 48 eQTLs for PROTEIN, representing 19 
unique eQTL genes, with 12 of those having gene symbols. Three eQTLs were in adrenal tissue, 
3 in pancreas tissue, and five in brain/pituitary tissue. Three of the brain eQTLs are in cerebellar 
tissues (all for gene transcripts with undefined gene symbols), while one is in hypothalamic 
tissue – these tissues were the only significantly enriched brain tissues for PROTEIN in the 
stratified LD Score regression analysis according to GTEx tissues. The eQTLs are driven by 
three loci: the diabetes locus on Chr. 2: 27 Mb, the alcohol consumption locus on Chr. 4: 100 
Mb, and the sweet-taste preference locus on Chr. 19: 49 Mb. 
SUGAR. Across all tissues, we find a total of 24 eQTLs for SUGAR, representing eight unique 
eQTL genes, with six of those having gene symbols. Out of these 24 eQTLs, 22 are driven by 
SNPs in the Chr. 19: 49 Mb locus. Interestingly, FGF21 (the putative causal gene in this sweet 
taste preference locus84) itself was not an eQTL gene, while other genes in this area IZUMO1, 
RASIP1, NTN5, SEC1P, MAMSTR are, as well as several other gene transcripts with undefined 
gene symbols. These findings underscore that, as is well known, eQTL data cannot be used as 
conclusive evidence for causality, but also leaves the possibility that other genes in this area (in 
addition to FGF21) may also have causal effects. The other two eQTLs are the lead SNP in the 
Chr. 8: 9 Mb locus; one was a pseudogene, while the other one is a novel, unstudied gene with an 
undefined gene symbol. 
CARBOHYDRATE. Across all genes, we find a total of 352 eQTLs for CARBOHYDRATE, 
representing 49 unique eQTL genes, with 30 of those having gene symbols. The eQTLs are 
mainly driven by the lead SNP rs36123991 and its LD partners, which has eQTLs in every single 
queried tissue; we find 306 eQTLs for these SNPs across tissues, accounting for 34 unique eQTL 
genes. This makes it difficult to pinpoint a single putative causal gene in this locus, but it 
indicates that the associated SNPs have widespread effects on gene expression. 
6.2.4 Predicted functions of MAGMA genes in Gene Network 
To gain insight into the functional architecture of the 81 significant MAGMA-genes identified 
across the four macronutrients (Supplementary Information 5.3), we query them in Gene 
Network (download date March 14, 2018). This database assigns genes with predicted functions 
on the basis of co-expression patterns. Across domains, we then count which functions surface 
most frequently. Gene Network uses information from expert-curated gene sets, and assess co-
expression between all measured genes and these gene sets. If a gene is co-expressed with the 
genes in the gene set, the gene is assigned the predicted function that belongs to that gene set. 
(These co-expression data are also used as input in the DEPICT130 software.) Note that we use 
this query of predicted gene functions as a way to gain rough insight into the putative biological 
functions of the MAGMA genes; this is not a formal test for statistical association. Moreover, it 
is important to keep in mind that the predicted functions are not independent, as MAGMA does 
not correct for LD between genes. The query therefore included several different genes from the 
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same locus, where it is possible that in every locus, only one of these queried genes was the 
actual causal one. 
In a nutshell, Gene Network predicts gene functions on the basis of co-expression data, as 
described in detail in Fehrmann et al.122 and Pers et al.130, and in previous SSGAC projects63,64,91. 
Gene Network was updated in late 2017 with new gene expression and annotation data.  
We record all Reactome pathways that were predicted to be relevant for the MAGMA genes at 
statistical significance (FDR-corrected P value < 0.05). We only record pathways that were 
predicted to be relevant in a positive direction (i.e., upregulated). All genes were available in 
Gene Network, with the exception of DCDC5, where more recent gene definitions from NCBI 
showed that this gene was merged with DCDC1, which was queried instead of DCDC5. 
The results for the top ten most frequently occurring terms are displayed in Supplementary 
Table 6.6. Here, we briefly summarize the results. The results show a mix of basic pathways 
involved in signal transduction (needed for cell growth, division and communication, and thus 
essential for viability), the immune system, lipid metabolism, and neuronal development. The top 
most predicted Reactome pathway is a tie between three pathways, which were predicted for 38 
(out of 81) genes: “Downstream signal transduction”, “Signaling by EGFR”, and “Signaling by 
PDGF”, where the latter pathway is actually the mother pathway to “Downstream signal 
transduction.” PDGF is short for platelet-derived growth factor, a basic growth factor needed for 
cell growth and division. EGFR is short for epidermal-derived growth factor which plays a role 
in various types of cancer. Several insulin-related pathways also occur: 31 genes have predicted 
functions for “IGF1R signaling cascade”, “Insulin receptor signaling cascade”, “IRS-related 
events triggered by IGF1R”, and “Signaling by type 1 insulin-like growth factor 1 receptor 
IGF1R.” With regards to neuronal development, we find that several genes have predicted 
functions for “Axon guidance” (31 genes) and several of its sub-pathways (31 genes for 
“L1CAM interactions” and 27 genes for “Semaphorin interactions”). With regards to 
metabolism, we find that several genes have predicted functions for pathways associated with 
lipid and energy metabolism (29 genes for “Fatty acid triacylglycerol and ketone body 
metabolism”, 28 genes for “Integration of energy metabolism”, 27 genes for 
“Glycerophospholipid biosynthesis”, and 27 genes for “Phospholipid metabolism”). 
In conclusion, we find no distinct biological pattern for these 81 MAGMA-genes in the Gene 
Network database of predicted gene functions. This stands in contrast to the LD Score 
partitioned regression findings, which point strongly to a role for the brain. Here, it seems that 
the top GWAS genes do not have a distinct neural function, which might have been predicted on 
the basis of the GWAS Catalog findings in Supplementary Information 5.5, where we seem to 
find more overlaps with metabolic traits at these loci than with psychological or psychiatric 
traits. 
6.3 Discussion of bioannotation results 
In our bioannotation of the genome-wide biological architecture and individual SNPs and genes, 
two major patterns emerged. First, we find widespread enrichment of the brain for diet 
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composition. Second, we find some evidence for enrichment in the adrenal/pancreas (for FAT) in 
the tissue demarcations that were based on chromatin data, although this was not replicated with 
the GTEx tissue demarcations. We currently do not know if the adrenal/pancreas enrichment is a 
spurious finding or is not replicated due to lack of statistical power in the GTEx data.  
For the GWAS SNPs and genes, we identify some interesting candidate loci and genes, as 
summarized in Supplementary Information 5.2, which might be valuable for future functional 
and fine mapping analyses. When the loci had been previously associated with another trait, this 
tended to be in GWAS of BMI, metabolic syndrome (e.g., dyslipidemia, fasting glucose and 
insulin) and diabetes. Most loci harbor a number of genes that were in LD with each other, 
making it difficult to point out candidate causal genes. Some loci re in large inversion 
polymorphisms associated with neurodegenerative disorders. Although many of the loci 
overlapped across the four phenotypes, some loci were (currently) only associated with one 
phenotype. Although our Gene Network query of MAGMA-genes is likely underpowered at this 
stage (with only 81 significant MAGMA genes to query), the MAGMA-genes did not clearly 
point to “brain genes”, with many predicted functions for signal transduction (especially for 
insulin) and lipid metabolism in addition to pathways related to neuronal development. The 
GWAS for BMI showed a similar pattern, as the genome-wide biological architecture points to 
the brain94,116, while the top gene locus (containing FTO and IRX3) seems to have a direct 
metabolic effect100. 
7 Genetic correlations between the phenotypes and sexes 
In this section, we examine the genetic and phenotypic correlations between the four 
macronutrients, as based on the results from the full meta-analysis. We also report the genetic 
correlations between sexes. 
7.1 Genetic correlations between macronutrients 
The results are summarized in Main Table 2. The only positive genetic correlation is between 
SUGAR and CARBOHYDRATE (?̂?𝑐𝑔𝑔= 0.73, SE = 0.02), which is highly statistically distinguishable 
from both zero and unity. We find that all phenotype pairs have a negative genetic correlation 
that is statistically distinguishable from zero at the 0.1% level, except for FAT and PROTEIN (?̂?𝑐𝑔𝑔= -
0.02, SE = 0.07) whose genetic correlation is negative but close to zero. 
In terms of the magnitudes of the correlations, the largest negative genetic correlation is between 
FAT and CARBOHYDRATE (?̂?𝑐𝑔𝑔= -0.61, SE = 0.03), and FAT and SUGAR (?̂?𝑐𝑔𝑔= -0.51, SE = 0.04). 
They are followed by PROTEIN and SUGAR (?̂?𝑐𝑔𝑔= -0.31, SE = 0.06) and PROTEIN and 
CARBOHYDRATE (?̂?𝑐𝑔𝑔= -0.23, SE = 0.05). 
Finally, we examine genetic correlations between the four macronutrients and SATURATED FAT 
(relative intake of saturated fat in the UKB), reported in Supplementary Table 7.2.  SATURATED 
FAT has significant genetic correlations with all four macronutrients, including PROTEIN (?̂?𝑐𝑔𝑔= -
0.121, P = 0.046). The latter is barely statistically distinguishable from zero at the 5% level. If 
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this genetic correlation is truly negative, it is surprising in light of the shared animal origin of 
protein and saturated fat (e.g., 131). The genetic correlations between SATURATED FAT and the 
other macronutrients also all statistically distinguishable from 1 or -1 (P < 4 × 10-20), indicating 
that SATURATED FAT has a genetic architecture that is partially unique from relative consumption 
of other macronutrients, including all fats (?̂?𝑐𝑔𝑔= 0.643, SE = 0.039).In Supplementary 
Information 10, we also report genetic correlations between the four macronutrients and 
absolute alcohol consumption (number of drinks weekly, not corrected for total energy intake). 
We find negative genetic correlations between the diet composition phenotypes and absolute 
alcohol intake that are statistically distinguishable from zero. A slight exception to this is FAT, 
which was also genetically negatively correlated with alcohol, while its P value did not surpass 
the Bonferroni-corrected significance threshold. 
7.1.1 Comparison to phenotypic correlations 
We compare the genetic correlations to the phenotypic correlations in four different cohorts 
(UKB, HRS, FHS and WHI). The genetic correlations outlined above generally mirror their 
phenotypic correlations. The results (with their 95% confidence intervals) are reported in 
Supplementary Table 7.3. 
Since sugars are a subset of carbohydrates, SUGAR and CARBOHYDRATE have a strong positive 
phenotypic correlation that is statistically significantly different from both zero (but also from 
one) in all cohorts (range:  ?̂?𝑐𝑖𝑖= [0.69, 0.79]).    
All other phenotypic correlations are negative and statistically significant in all cohorts. In 
increasing order these range from CARBOHYDRATE-FAT (range: ?̂?𝑐𝑖𝑖= [-0.79, -0.54]), SUGAR-FAT 
(range:  ?̂?𝑐𝑖𝑖= [-0.62, -0.41]), CARBOHYDRATE-PROTEIN (range: ?̂?𝑐𝑖𝑖= [-0.39, -0.09]), SUGAR-PROTEIN 
(range: ?̂?𝑐𝑖𝑖= [-0.30, -0.08]). When we compare these phenotypic correlations with genetic 
correlations from the previous section, the only genetic correlation that does not fall within its 
corresponding phenotype interval for these four cohorts is SUGAR-PROTEIN (?̂?𝑐𝑔𝑔 = -0.31). 
7.2 Genetic correlations between sexes 
Finally, we assess the genetic correlations between sexes for the four macronutrients in the UKB. 
The results are summarized in Supplementary Table 7.4. None of the point estimates are 
distinguishable from 1 (smallest rg = 0.751, SE = 0.163 for PROTEIN). Hence, we currently do not 
find evidence that relative macronutrient intake has a sex-specific genetic architecture. 
8 Estimation of SNP-based heritability 
Previously, twin studies have shown moderate heritability for macronutrient ratios (h2 = 27-
70%)132–134. In this section, we employ GREML (implemented by GCTA56) and LD Score 
regression67 to obtain empirical estimates of SNP-based heritability of diet composition, as 
represented by the four macronutrients. Previous SNP-based estimates of heritability for relative 




8.1.1 The GCTA method 
The GCTA56 method for estimating SNP-based heritability is based on restricted maximum-
likelihood estimation and uses the genetic relatedness matrix (GRM) to estimate the SNP 
heritability. Under certain assumptions56, the method yields unbiased estimates of SNP-based 
heritability. However, it is necessary to limit the number of SNPs and individuals in the analysis 
in order for it to be computationally tractable. To this end, we follow the procedure described in 
Karlsson Linnér et al.51. That is, we restrict the GCTA analysis to a random subset of 30,000 
individuals in the UKB. To then obtain a set of unrelated individuals, we thereafter drop one 
individual in each pair of individuals with a cryptic relatedness exceeding 0.025, resulting in N = 
28,635. The results are summarized in Supplementary Table 8.1. In total, 633,335 directly 
genotyped SNPs with MAF > 0.01 were included in the GCTA heritability estimation. 
8.1.2 The LD Score regression method 
Another method for obtaining SNP-based heritability estimates is LD Score regression67. The 
method is based on assumptions that imply that a SNP’s GWAS 𝜒𝜒2-statistic is linearly related to 
its LD Score, with SNPs with higher LD Scores having a higher likelihood of association in a 
GWAS. A SNP’s LD Score simply is the sum of the squared correlation coefficients between a 
SNP and all the other SNPs it is in LD with (as measured in a particular reference panel). The 
slope of the LD Score regression (i.e., of the SNPs’ GWAS 𝜒𝜒2-statistics on their LD Scores) can 
then be rescaled to obtain an estimate of SNP-based heritability. In practice, LD Score regression 
is commonly viewed as giving a lower bound of heritability from common SNPs135. An 
advantage of LD Score regression is that it is calculated from the GWAS summary statistics and 
thus uses data from all individuals included in the GWAS. 
The LD Scores used in this analysis were computed by Finucane et al.116 with genotypes from 
the European-ancestry samples in the 1000 Genomes Project (the “eur_w_ld_chr” files). 
Subsequently, only HapMap3 SNPs with MAF > 0.01 are included in the LD Score regression, 
as these ~1.2 million SNPs are well-known to be imputed properly across individual cohorts. Of 
note, we do not apply GC to the summary statistics prior to estimating the LD Score regressions. 
8.2 Results and discussion 
The results of the heritability estimations are reported in Supplementary Table 8.1 and 
displayed in Extended Data Figure 7. The GCTA-estimated heritability estimates range from 
h2GCTA = 0.021 (SE = 0.017) for PROTEIN to h2GCTA = 0.079 (SE = 0.018) for CARBOHYDRATE. The 
LDSC-estimated heritability estimates range from h2LDSC = 0.028 (SE = 0.002) for PROTEIN to 
h2LDSC = 0.047 (SE = 0.004) for SUGAR. These estimates are more similar in magnitude to 
behavioral traits such as educational attainment64,66, subjective wellbeing63 and risk 
preferences91, than BMI and obesity94,136. While the estimates are small, they imply a non-
ignorable biological component that affects dietary patterns. 
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It is important to note that the heritability estimates for diet composition may be affected by 
measurement error, caused by for instance the random noise induced by the 24-hour dietary 
recall measurement in UKB (Supplementary Information 2.5.3) and imperfect measurement 
(e.g., recall error, imperfect stability of dietary habits) of dietary intake in general. Second, there 
are generic reasons for the missing heritability we observe. Twin estimates of narrow-sense 
heritability might be overestimated for various reasons, including genetic nurture137 and only 
partially capturing non-linear genetic effects138. Moreover, our estimates only capture variation 
due to measured genetic markers, while unobserved genetic markers (e.g., very rare variants or 
structural variants that are not well tagged by measured SNPs) might also contribute to the 
heritability of eating behaviors. Similar studies for traits like height and BMI suggest that this 
“still missing heritability” tends to disappear once fully sequenced genetic data is used139. 
However, we are limited to studying the data that is currently available. 
Genetic analysis of a phenotype can be of interest even if the true heritability of a phenotype is 
low, for a variety of reasons. Perhaps most importantly, a genetic analysis may shed light on 
biological mechanisms. This is valuable in itself but could also provide knowledge that 
ultimately leads to new treatments. Even if naturally occurring variation in genes explain little of 
the variance in the phenotype, the biological pathway through which they operate could matter if 
intervened upon. Notable examples are hypercholesteremia and schizophrenia, where drugs that 
target specific genes have large therapeutic benefits, while the common genetic variants that lie 
in these genes only have small effect sizes in GWAS71,72. Dietary intake might be affected 
pharmacologically by drugs that target FGF21, which are currently on trial for diabetes and 
obesity140. 
9 Out-of-sample prediction 
In this section, we assess the out-of-sample predictive power of polygenic scores (PGS) for the 
four diet composition phenotypes. We use European-ancestry individuals, as based on both self-
reported and PC-based identification, in two of our cohorts as holdout samples: The Health and 
Retirement Study (HRS, N = 2,344) and the Rotterdam Study I (RSI, N = 3,585). While HRS and 
RSI were included in the full meta-analyses, we perform two additional meta-analyses which 
excluded HRS and RSI respectively, which is necessary to prevent overfitting. Here, we first 
describe the methods used to generate the polygenic scores and elaborate on how we measure 
prediction accuracy. Next, we report the predictive power for each phenotype and prediction 
cohort. 
9.1 Method 
A polygenic score for an individual, denoted 𝑃𝑃𝑃𝑃𝑆𝑆𝚤𝚤� , can be constructed as a weighted sum of his 
or her genotypes at J loci: 





where 𝑤𝑤𝑗𝑗 is the weight applied to SNP j and 𝑒𝑒𝑖𝑖𝑗𝑗 is the genotype of individual i at SNP j. 
Methodologies for PGS construction are determined by (i) how the weights 𝑤𝑤𝑗𝑗 are generated, and 
(ii) which J loci are included in the calculation. 
In order to generate the weights 𝑤𝑤𝑗𝑗, we used LDpred estimation, a Bayesian approach that 
weights each SNP by its conditional effect, given those of other SNPs141. In general, LDpred has 
been found to perform better than other, “cruder” approaches (e.g., pruning and thresholding)141. 
We performed LDpred estimation with a Gaussian prior for the distribution of effect sizes set to 
1. We used cohort-specific genotype data as the reference sample for LD estimation after 
excluding related individuals and ancestry outliers. 
We construct the scores based on only those SNPs in the HapMap consortium phase 3 release142 
that meet certain quality-control thresholds. For HRS, we only retain those variants with a call 
rate greater than 98% and without any problematic features from a known liste. For RSI, we filter 
out the SNPs with imputation quality (INFO) < 0.7, MAF < 0.05, and HWE P value < 0.001. 
Applying these thresholds to genotypic data of our prediction cohorts yields 1,144,445 and 
1,137,088 SNPs for HRS and RSI, respectively. 
We calculate the LD-adjusted weights with the LDpred software in our HRC reference panel 
(Supplementary Information 3.3.1) and obtain the final scores with PLINK by multiplying the 
genotype at each SNP by the corresponding LDpred-calculated weights and then summing over 
all included SNPs. 
9.2 Prediction model and prediction accuracy 
Our prediction analyses consist of running two ordinary least squares (OLS) regressions for each 
phenotype. First, we regress a phenotype on the following set of baseline covariates: sex, year of 
birth, year-of-birth squared, sex × year of birth and sex × year-of-birth squared, and the first 10 
principal components (PCs) of the cohort-specific genotype matrix. Next, we run the same 
regression but with the polygenic scores included as one of the independent variables. Our 
measure of interest that captures the prediction accuracy is the incremental adjusted R2, defined 
as the difference between the adjusted R2 of these two regressions. We bootstrapped 95% 
confidence intervals for the incremental adjusted R2 with the bootstrap percentile method and 
1,000 iterations. Since the incremental adjusted R2 can be negative, its confidence interval may 
also have a negative lower bound. 
9.3 Results 
Our prediction results are summarized in Supplementary Table 9.1 and Extended Figure 7. 
The table reports some summary statistics for the regression sample, the estimated incremental 
adjusted R2, and P value of the estimated coefficient on the score for each phenotype and 
 
 




prediction cohort. Overall our polygenic scores explain 0.08% to 0.71% of the variation in 
dietary composition.  
FAT. The incremental adjusted R2 of the scores is 0.27% and 0.20% for the HRS and RSI cohorts, 
respectively. The estimated regression coefficients for the scores are distinguishable from zero 
(P < 0.01) for both cohorts.  
PROTEIN. In the HRS, the incremental adjusted R2 of the scores is 0.08%. In the RSI, we estimate 
a relatively greater predictive power, with incremental R2 of 0.31%. While the estimated 
regression coefficient on the scores is not distinguishable from zero for HRS (P = 0.088), it is for 
RSI (P = 0.0005). 
SUGAR. In the HRS, the incremental adjusted R2 of the scores is 0.64%. In the RSI, we estimate 
an incremental R2 of 0.62%. The estimated regression coefficients for both scores are highly 
distinguishable from zero (P < 0.0005). 
CARBOHYDRATE. In the HRS, the incremental adjusted R2 of the polygenic scores is 0.71%. In 
the RSI, we estimated a relatively smaller predictive power, with incremental R2 of 0.38%. The 
estimated regression coefficients for both scores are distinguishable from zero (P < 0.0005). 
9.4 Discussion 
Overall, the difference in predictive power between phenotypes follows the difference in SNP-
based heritability between phenotypes. That is, PROTEIN has the lowest estimates of SNP-based 
heritability, followed by FAT, CARBOHYDRATE and SUGAR. These analyses indicate that PROTEIN 
needs a larger sample size for genetic discovery to reach the same out-of-sample predictive 
power as the other macronutrients. For all macronutrients, larger GWAS discovery samples are 
needed for the polygenic scores to reach the the SNP-based heritability (which is the upper 
bound of variance that could be explained by a polygenic score). 
Furthermore, we note that the predictive accuracy of the polygenic scores might be attenuated by 
the discrepancy of methods between the meta-analysis cohorts and holdout cohorts. That is, our 
meta-analyses consisted mainly of the UKB, which used a 24HDR method, while the holdout 
cohorts HRS and RS both used FFQs (Supplementary Table 1.2). This discrepancy in methods 
could downwardly bias genetic correlations between the meta-analysis and holdout cohorts, 
which would attenuate the predictive accuracy of the polygenic score143. Another source of 
imperfect genetic correlation between meta-analysis and holdout cohorts could be driven by 
cultural differences in eating habits. This could happen if cultural differences interact with 
genetic background, such that genetic factors have culture-specific influences on eating habits. 
However, we do note that the confidence intervals for the explained variance largely overlap 
between HRS and RS (see Extended Data Figure 8 and Supplementary Table 9.1). Since the 
differences in point estimates may not be meaningful, we refrain from further speculation. 
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10 Genetic correlations with health and behavior 
In this section, we estimate the extent of genetic overlap between our main phenotypes and a 
total of 33 relevant (mental) health and behavior measures. These span anthropometric, 
glycemic, cardiometabolic, lipid, socioeconomic, lifestyle, and neuropsychiatric domains. The 
rationale behind inclusion of each trait is summarized in Supplementary Table 10.1. We pre-
registered a selection of 19 traits of interest in our publicly available analysis plan on Open 
Science Framework (July 2017). The five traits that were added later, and thus not pre-registered 
were: Alzheimer’s disease (included because of our finding of an APOE association), physical 
activity level (included because it is clearly relevant for diet, and 23andMe provided this data as 
part of our collaboration), alcohol consumption (included because of our finding of an ADH1B 
association), Townsend Deprivation Index (informed by UKB data availability, and included 
because of the relationship between built environments and food intake144), and Anorexia 
Nervosa (informed by Psychiatric Genomic Consortium data availability, included because it is 
an eating disorder with both metabolic and behavioral causes that are relevant to dietary intake).  
Later, we added an additional nine psychiatric traits, in order to further explore the genetic 
overlap between diet composition and psychiatric health (ADHD145, alcohol dependence146, 
autism spectrum disorder147, bipolar disorder148, depressive symptoms63, depression149, PGC 
cross-disorder analysis150, schizophrenia72, and subjective wellbeing63). The 23andMe physical 
activity findings were also updated in early 2019, as the GWAS sample size increased from N = 
123,983 to N = 269,189. 
Because we examine our four diet composition phenotypes and 33 other variables, we are at risk 
of finding spurious associations due to multiple hypothesis testing. To correct for this, we make a 
Bonferroni correction for 33 traits to the P value of each genetic correlation, and we only discuss 
results that are statistically significant after this correction. Since many of the phenotypes of 
interest are themselves genetically correlated, Bonferroni is over-conservative. While this 
ensures we are unlikely to find spurious results, it also means we may overlook some true 
correlations that do not meet Bonferroni significance. 
The summary statistics for the majority of relevant health traits and behaviors are from LD 
hub136, as indicated in Supplementary Table 10.2. The other traits are analyzed in accordance 
with the LD hub protocol to establish comparability (i.e., excluding the HLA region and any 
SNPs with χ2 > 80).  
Physical activity level was measured in a sample of N = 269,189 participants from 23andMe 
(unpublished data). The 23andMe physical activity phenotype is based on a calculation of MET-
minutes per week for various activities as a continuous trait, as described in the guidelines for 
data processing for the International Physical Activity Questionnaire (IPAQf). The short form of 
the IPAQ was deployed on the 23andMe website to 23andMe research participants. Participants 






in calculating MET-minutes. MET-minutes were first log-transformed. Then, for each sex 
separately, we regressed out age, age-squared, age-cubed, the first ten ancestry principal 
components, and the platform used to genotype participants, and quantile-normalized the 
residuals. The results were combined across sexes, and the GWAS was ran on this phenotype, 
controlling for age, age-squared, age-cubed, sex, sex × age, sex × age-squared, sex × age-cubed, 
the first ten principal components, and the platform used to genotype participants 
Townsend Deprivation Index and alcohol consumption (number of drinks weekly) are based on 
GWAS on the first release of the UKB, as described in Karlsson Linnér et al.51. Townsend 
Deprivation Index is a measure of the average socioeconomic status of the participant’s housing 
area. It was calculated by the UKB on the basis of area unemployment rates, non-car ownership, 
non-house ownership, and overcrowding151. Higher scores indicate higher deprivation. Scores 
were assigned by UKB on the basis of the postal code of the participant’s household address.  
College completion64 and height152 are based on the most recent and publicly available GWAS 
summary statistics from 2016 and 2014, respectively, as LD hub only contained older summary 
statistics for these two traits. 
10.1 Method 






where 𝜎𝜎�𝑔𝑔 is the genetic covariance between traits 𝑒𝑒1 and 𝑒𝑒2 as estimated using bivariate LD 
Score regression67,153, and  ℎ�𝑔𝑔𝐷𝐷
2  is the heritability of trait 𝑒𝑒𝑖𝑖 as estimated using univariate LD 
Score regression for each trait individually. 
Under a set of assumptions, bivariate LD Score regression produces unbiased estimates of 
genetic covariance, 𝜎𝜎𝑔𝑔, using GWAS summary statistics for the two traits of interest and an LD 
Score reference panel. The LD Score reference panel captures the level of genetic variation that 
is tagged by a single SNP. We use LD Scores based on the European-ancestry individuals in the 
1000 Genomes Project, which were computed by Finucane et al.153. We restrict our analysis to 
HapMap3 SNPs (with MAF > 0.01), which guarantees that all analyses are performed using a set 
of SNPs that are imputed with reasonable accuracy across all cohorts. We estimate standard 
errors using the LDSC software that uses a block jackknife over the SNPs. 
10.2 Association with psychiatric traits 
Our study is relevant to the newly emerging field of “nutritional psychiatry”154,155, which takes a 
holistic approach to mental health. The central aim of nutritional psychiatry is to improve mental 
health in ways other than pharmacological intervention155. Specifically, it studies the effects of 
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nutrition on mental health, as mediated by nutritional effects on brain health, systemic 
inflammation, and the gut microbiome156,157. 
To provide empirical evidence relevant for nutritional psychiatry, we include additional genetic 
correlation analyses between the four macronutrients and nine psychiatric traits. These analyses 
take advantage of the fact that genetic correlations between macronutrient intake and mental 
health can now be estimated without the need to observe psychiatric diagnoses and 
macronutrient intake in the same samples67, thus enabling new discoveries about relationships 
between diet and mental health.  
In the literature, there is currently mixed evidence for the benefits of nutritional interventions in 
psychiatric illness. This may partly be caused by the fact that nutritional interventions are 
difficult to blind and subject to large placebo effects158. There is some evidence that fish oils 
(polyunsaturated omega-3 or 6 oils) have beneficial effects on depression159, although recent 
experimental trials of more comprehensive dietary interventions have produced mixed 
results158,160. Associations between nutrition and psychiatric disorders outside of the mood 
spectrum, such as ADHD, remain controversial161,162. Overall, there are few studies that examine 
the effect of relative macronutrient intake on mental health163. One recent randomized trail found 
evidence that low-fat diets might have mental health benefits, while a review of small-scale trials 
found that psychosocial benefits are usually dependent on weight loss and independent of 
macronutrient composition163. Hence, the results from our exploratory genetic correlation 
analyses could be used to put forward novel hypotheses for relationships between relative 
macronutrient intake and psychiatric conditions. 
10.3 Results 
The results are displayed in Supplementary Table 10.2 and Figure 3. We briefly summarize 
them here. 
10.3.1 Genetic correlations with health 
CARBOHYDRATE and SUGAR. Since the patterns of genetic correlations for CARBOHYDRATE and 
SUGAR are similar, we jointly summarize them here. We find significant negative genetic 
correlations between carbohydrate and sugar consumption and several measures of body fat 
composition: waist circumference (CARBOHYDRATE: rg = -0.142, SE = 0.033, SUGAR: rg = -0.132, 
SE = 0.033) and waist-to-hip ratio (CARBOHYDRATE: rg = -0.175, SE = 0.037, SUGAR: rg = -0.147, 
SE = 0.037). We also find a weak but significant negative genetic correlation between 
CARBOHYDRATE (though not SUGAR) and HDL (“good”) cholesterol (rg = -0.125, SE = 0.040). 
PROTEIN. We find statistically highly significant and positive genetic correlations between 
PROTEIN and several measures of obesity including childhood obesity (rg = 0.304, SE = 0.062), 
BMI (rg = 0.402, SE = 0.041), overweight (i.e., BMI > 25, rg = 0.383, SE = 0.045), obesity class 
I (i.e., BMI > 29, rg = 0.352, SE = 0.040), waist circumference (rg =  0.369, SE = 0.041) and 
waist-to-hip ratio (rg = 0.279, SE = 0.039). These correlations with obesity are accompanied by 
positive correlations with several related diseases: type 2 diabetes (rg = 0.445, SE = 0.062), 
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fasting insulin (rg = 0.411, SE = 0.08) and coronary artery disease (rg = 0.155, SE = 0.04). There 
is also a negative correlation with HDL (“good”) cholesterol (rg = -0.250, SE = 0.05). 
FAT. After Bonferroni correction, we do not find any significant genetic correlations between 
FAT and health-related outcomes. 
10.3.2 Genetic correlations with socioeconomic status and lifestyle 
In this section we explore genetic correlations of dietary intake with socioeconomic, lifestyle and 
neuropsychiatric outcomes. We find several genetic correlations that are statistically significant 
after Bonferroni correction.  
CARBOHYDRATE and SUGAR. Both CARBOHYDRATE and SUGAR have negative genetic correlations 
with the Townsend deprivation index (CARBOHYDRATE: rg = -0.298, SE = 0.06, SUGAR: rg = -
0.231, SE = 0.064). This suggests that living in a lower socioeconomic region is associated with 
consuming relatively less energy from carbohydrates and sugars. We also find positive genetic 
correlations between physical activity and SUGAR (rg = 0.225, SE = 0.042) and CARBOHYDRATE 
(rg = 0.13, SE = 0.04). Thus, individuals who are more genetically prone to being physically 
active tend to have higher proportions of sugar intake in their diet. (CARBOHYDRATE’s weak 
positive genetic correlation with physical activity is not statistically significant after Bonferroni 
correction.) Both CARBOHYDRATE and SUGAR have negative genetic correlations with alcohol 
consumption (rg = -0.605, SE = 0.027 for CARBOHYDRATE, and rg = -0.399, SE = 0.032 for 
SUGAR).  
PROTEIN. The only SES or lifestyle outcome that correlates genetically with PROTEIN is alcohol 
consumption (rg = -0.158, SE = 0.040). 
FAT. FAT is the only macronutrient that has significant genetic correlations with educational 
attainment. Both college completion and years of education show a negative genetic correlation 
(rg = -0.131, SE = 0.036 for college completion, and rg = -0.105, SE = 0.033 for years of 
education), implying that individuals with a lower genetic prediction for education consume 
relatively more FAT. We also find that there is a significant negative genetic correlation between 
FAT and physical activity (rg = -0.321, SE = 0.04). This stands in contrast with the positive 
genetic correlation found between SUGAR and physical activity. 
The genetic correlation between FAT and alcohol consumption is borderline significant (P = 
0.055) after Bonferroni correction (rg = -0.112, SE = 0.037), which makes FAT the weakest and 
least correlated trait with alcohol consumption. 
SATURATED FAT. Relative intake of saturated fat has significant genetic correlations with BMI (rg 
= -0.115, SE = 0.035) and weekly alcohol consumption (rg = -0.112, SE = 0.037). None of the 
other body fat indicators were significantly genetically correlated with SATURATED FAT, however, 
making this isolated finding hard to interpret. Alcohol dependence was also not genetically 
correlated with SATURATED FAT. This pattern stands in partial contrast with the genetic 
correlation pattern of total FAT, which did not have a significant genetic correlation with BMI (rg 
= -0.017, SE = 0.047). SATURATED FAT did not have genetic correlations with educational 
attainment that were statistically distinguishable from zero (rg = -0.10, SE = 0.04 for EduYears), 
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although they were similar in magnitude to FAT’s genetic correlations with educational 
attainment rg = -0.13, SE =0.04 for EduYears), which were statistically distinguishable from 
zero.     
10.3.3 Correlations with neuropsychiatric outcomes 
Between neuropsychiatric phenotypes and macronutrient intake, the only significant genetic 
correlations after Bonferroni correction are between ADHD and CARBOHYDRATE (rg = -0.189, SE 
= 0.044) and between schizophrenia and SATURATED FAT (rg = -0.133, SE = 0.037). 
Despite APOE associations with FAT, SUGAR, and CARBOHYDRATE, there are no detectable 
(genome-wide) genetic correlations with Alzheimer’s disease. CARBOHYDRATE and FAT show 
significant genetic correlations (positively, and negatively, respectively) with Anorexia Nervosa 
that lose significance after Bonferroni correction. Subjective wellbeing has a positive genetic 
correlation with SUGAR, (rg = 0.135), but this is not significant after Bonferroni correction 
(PBonferroni = 0.13). Finally, we note that none of the macronutrients had significant genetic 
correlations with alcohol dependence. This might indicate that the negative genetic correlations 
with weekly alcohol consumption described above are indicative of substitution effects. 
10.4 Discussion 
We find the largest and most widespread positive genetic correlations with poor health for 
PROTEIN. PROTEIN correlates genetically with all included obesity indicators (BMI, overweight, 
obesity, waist circumference, and waist-hip ratio) and childhood obesity, as well as related 
diseases and disease states (type 2 diabetes, fasting glucose and insulin, insulin resistance, 
coronary artery disease, and HDL cholesterol). 
As with any correlation, it is impossible to infer a causal mechanism. Possible explanations 
might be that protein intake causally predisposes to obesity and metabolic syndrome, but other 
plausible explanations might be that obesity-prone individuals have a higher protein need, that 
overweight individuals use high-protein diets as a weight-loss strategy, or that the correlation is 
due to confounding by an unmeasured third variable (which may be environmental or genetic). 
The effect may also be mediated by a combination of the other diet composition phenotypes, as 
they are correlated with each other (Supplementary Information 7). 
However, a causal role for protein (and especially meat) intake in the development of metabolic 
syndrome has been postulated164–167. If true, this causal effect of protein intake would contravene 
the view that protein intake should be increased due to its desirable effects of reducing hunger 
and increasing satiety168–170. It also contravenes a “Paleolithic” view of optimal dietary intake, 
which argues that energy intake from animal protein should be increased at the expense of 
carbohydrates, with the average Westerner consuming about 15% of energy from protein, 
compared to 19% for the average contemporary hunter-gatherer157. 
In terms of the socioeconomic and lifestyle indicators, we find that FAT genetically correlates 
with lower educational attainment (with small, negative genetic correlations with college 
completion and years of education, rg = -0.131, SE = 0.036 for college completion). The genetic 
correlation with Townsend deprivation index was not significant after Bonferroni correction (rg = 
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0.193, SE = 0.066). CARBOHYDRATE and SUGAR genetically correlate with indicators of higher 
socioeconomic status (where both have a negative correlation with Townsend deprivation index) 
but not with educational attainment (rg < 0.05). More research is needed to clarify the reasons for 
these relationships.   
We could speculate that the genetic overlap between diet composition and socioeconomic 
variables could be caused by horizontal (or “biological”) pleiotropy, for instance through 
involvement of shared neural mechanisms that independently affect both educational attainment 
and diet composition. For instance, an underlying genetic factor for self-control could 
independently affect educational attainment and dietary habits. However, it is also possible that 
educational attainment affects dietary choices (i.e., vertical pleiotropy). The genetic correlations 
between CARBOHYDRATE/SUGAR and neighborhood deprivation could also be caused by 
environmental channels, such that individuals who live in deprived neighborhoods have 
restricted access to fresh high-carbohydrate foods such as bread and fruit/vegetables171 (another 
example of vertical pleiotropy). Of course, the genetic overlap we found could also be spurious, 
caused by a third, unmeasured variable that confounds the relationship. These three scenarios 
(horizontal pleiotropy, vertical pleiotropy, and confounding) have different causal biological 
interpretations. In the phenotypic correlation analyses reported in Supplementary Information 
11.2.2, we find that FAT has a small but consistent association with lower socioeconomic status, 
while CARBOHYDRATE surprisingly is associated with less neighborhood deprivation. Future 
research with the necessary data could explore these associations further, for instance with 
models that assess the mediating effect of self-control, or with Mendelian Randomization 
designs that test the causal influence of education and neighborhood deprivation on diet 
composition.  
The positive genetic correlations between SUGAR and CARBOHYDRATE with physical activity, and 
the negative genetic correlation between FAT and physical activity, could explain some of the 
other patterns we observe. For instance, it is possible that the “favorable” genetic correlations 
between SUGAR and body fat composition (and the lack of genetic correlations with obesity and 
related diseases) are explained by the association between physical activity level and SUGAR. We 
explore this explanation in the phenotypic analyses in the next section (Supplementary 
Information 11), where we adjust the phenotypic associations between the macronutrients and 
BMI for physical activity in the UKB. There, we find that the phenotypic associations between 
relative sugar and carbohydrate intake become smaller but remain significant. 
In the neuropsychiatric domain, we find two significant genetic correlations (ADHD and 
CARBOHYDRATE, rg = -0.189; schizophrenia and SATURATED FAT, rg = -0.133). One randomized-
controlled study found that a restricted “few foods” diet significantly improves ADHD 
symptoms in young children with ADHD162, although this diet does not focus on carbohydrates, 
but on foods that trigger allergic reactions. The relationship may also be confounded by 
socioeconomic status, as CARBOHYDRATE also show a significant negative genetic correlation 
with neighborhood deprivation. The genetic correlation between saturated fat and schizophrenia 
is in the opposite direction of what could be expected, since the diets of schizophrenia patients 
are typically of poorer quality, with higher consumption of saturated fats172.  
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Finally, we note that the genetic correlations should be interpreted with the heritability estimates 
of diet composition in mind. That is, genetic covariance between traits with low heritability may 
only explain a very small proportion of the total covariance of two traits. 
10.4.1 Comparison to genetic correlations from Merino et al.  
In their GWAS of relative intake of carbohydrate, fat, and protein (defined as percentage of total 
energy intake), Merino et al. (N = 123,659) also assessed genetic correlations with various 
physical and mental health phenotypes. Specifically, they assessed genetic correlations with 
BMI; type 2 diabetes; coronary artery disease; various circulating fatty acids; fasting insulin and 
glucose; inflammatory bowel syndrome; years of education; and the psychiatric disorders 
schizophrenia, depression, anorexia nervosa, and bipolar disorder. In their Supplementary Figure 
S6 they report their results. We compare our findings in Supplementary Table 10.4. P values 
and standard errors were not reported by Merino et al., but effect estimates were printed in bold 
if they surpassed their Bonferroni-corrected significance threshold for 51 tests. We can roughly 
estimate their standard errors by multiplying our standard errors by the ratio of maximum sample 
sizes: 𝑆𝑆𝐸𝐸𝑀𝑀𝑖𝑖𝑠𝑠𝑖𝑖𝑛𝑛𝑜𝑜 = 𝑆𝑆𝐸𝐸𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝐶𝐶 × �264,181/123,659 = 𝑆𝑆𝐸𝐸𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝐶𝐶 × √2.14 . We use these estimated 
standard errors to calculate 95% confidence intervals, and report whether our confidence 
intervals overlap with those of Merino et al. 
After a conservative Bonferroni correction for 51 tests, the only significant genetic correlations 
reported by Merino et al. are between BMI and protein (rg = 0.23, compared to our rg = 0.40), 
and fat and years of education (rg = -0.24, compared to our rg = -0.11). Other genetic correlations 
with protein intake are in the same direction, but differ in magnitude, with ours being larger in 
magnitude compared to those found by Merino et al. However, the confidence intervals of all 
reported genetic correlations, with one exception (relative carbohydrate intake and depression), 
overlap. Hence, we conclude that our genetic correlation estimates do not statistically differ from 
those reported by Merino et al. 
11 Phenotypic associations between diet composition and BMI, 
SES, and alcohol abstinence 
We examine the phenotypic associations between relative macronutrient intake and BMI in four 
large, independent cohorts from the UK and US (UKB, HRS, FHS, and WHI, with combined N 
= 173,165; Supplementary Table 11.1). In the HRS, FHS, and WHI, we are also able to 
distinguish animal vs. plant protein, natural vs. added sugars (only available in a subset for FHS), 
and saturated vs. unsaturated fat. In the UKB, only the distinction between saturated vs. 
unsaturated fat is available. 
We focus on BMI, as it is readily available in all cohorts, and it is the most important proxy for 
metabolic syndrome, which is characterized by central obesity, high blood pressure, 
dyslipidemia, glycemia and insulin resistance, and consequentially cardiovascular disease and 
type 2 diabetes. Since the validity of BMI as a measure of adiposity is sometimes questioned173, 
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we also report the associations between BMI and DEXA-scan measures of body fat in UKB, 
which is considered the “gold standard” measurement of adiposity.  
Finally, we report associations between diet composition and indicators of socioeconomic status: 
completed years of education, household income, and the Townsend deprivation index. 
11.1 Method 
We estimate the standardized regression coefficients obtained from a 1) a simple regression of 
BMI on the focal macronutrient, and 2) a multiple regression of BMI on the focal macronutrient, 
sex, age, educational attainment, household income (available for all cohorts except FHS), and 
the number of measurements (for FHS, UKB, and WHI). In the UKB, we perform an additional 
regression that included a measure of overall physical activity. To ensure comparability, we 
restrict the simple regression in (1) to the set of individuals who had information on all 
covariates included in (2), and we only include individuals that were also included in the GWAS.  
We always utilize the best available measures of dietary intake and BMI, which ideally would be 
balanced (i.e., measured at the same time). If several simultaneous BMI and dietary intake 
measurements were available (i.e., in FHS and WHI), we use their averages. In the HRS, BMI 
(last measured in 2010) was not measured during the dietary intake measurement (only measured 
in 2013), so we take the most recent available BMI report from 2010. In the UKB, a similar 
situation arises, as the additional online dietary intake questionnaires took place after the BMI 
measurement at baseline in the assessment center. Despite these differences in measurement, the 
pattern and magnitude of associations are strikingly similar across cohorts. 
Making use of Fisher’s Z-transformation, we performed fixed-effects, inverse-variance weighted 
meta-analysis of the standardized regression coefficients. Fisher’s Z-transformation is also used 
to obtain 95% confidence intervals. Figure 4 summarizes the estimates from the adjusted model 
in forest plots. 
11.1.1 Framingham Heart Study 
In FHS, we average the dietary intakes across several measurement waves (exam 20-22 for the 
original cohort, exam 5-8 for the offspring cohort, and exam 1-2 for the generation 3 cohort), and 
perform the log-log regressions with these average intakes. The measure of BMI used in this 
analysis is the average BMI across the same measurement waves. For the adjusted model, we use 
the following covariates: educational attainment (years of education), which was taken from the 
Neuropsychological Battery; the total number of dietary intake measurements; and sex and birth 
year.  
11.1.2 Health and Retirement Study 
One dietary intake measurement was available in HRS, which was part of the 2013 Health Care 
and Nutrition Study (HCNS). We use the most recent available measures of BMI and household 
income (wave 10, 2010). Educational attainment is measured by total years of schooling.  
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11.1.3 UK Biobank 
In UKB, we average the total and macronutrient intakes across the five measurement waves (one 
at the assessment center and four additional online measurements), corrected for the day of the 
week the intake was reported (Supplementary Information 2.5.2). The assessment center 
measurements took place in 2009 and 2010, and the online measurements took place in 2011 and 
2012. BMI was measured at the assessment center. Educational attainment is measured as total 
years of schooling. Household income was self-reported in four categories (coded as dummies in 
the regression) at the assessment center visit. For the adjusted model, we use the following 
covariates: educational attainment (years of education); household income; Townsend 
deprivation index; the total number of dietary intake measurements; and sex and birth year. 
In addition to corrections for the demographic and socioeconomic variables described above, we 
estimate a third model in the UKB that includes covariates for physical activity (Supplementary 
Table 11.1) and self-reported walking pace. The physical activity measure is available for 
virtually all participants with dietary data in the UKB, as it was measured with three questions 
that were appended to the dietary intake questionnaire. Specifically, participants were asked how 
many minutes of light, moderate, and vigorous physical activity they performed the day before. 
We convert these answers into metabolic units in accordance with Anderson et al.174 and then 
summed and log-transformed. 
11.1.4 Women’s Health Initiative 
For WHI, we average the total macronutrient and energy intakes across years 0 through 10, and 
we used these average intakes in the phenotype construction. The BMI measure we use is  the 
average BMI across years 0 through 10. For educational attainment, we use dummies for the 
“highest grade finished in school” variable. For household income, we use the most recent value 
of family income available (from year 6, year 3, or baseline, where the variables of year 3 and 
baseline were re-mapped to the year 6 categories). Additional covariates in the adjusted model 
are birth year, the number of dietary intake measurements, the number of BMI/dietary intake 
measurements, and dummies for the year from which family income was derived.  
11.1.5 Associations between BMI and objective measures of adiposity in the UKB 
In these analyses we focus on BMI, which is measured in almost all population cohorts and is 
related to a myriad of health outcomes. BMI is designed to be a measure of weight that is 
unrelated to height in order to derive an estimate of adiposity (the component of the variance in 
weight that is unrelated to body height and must therefore be due to variation in body mass).  
As we reported earlier in Supplementary Information 2.6, we find that height squared is the 
correct empirical adjustment factor for height in the UKB, as a log-log regression of weight on 
height yielded a coefficient of ?̂?𝛽 = 1.9995. However, BMI is not a perfect measure of adiposity: 
while it has a high level of specificity (0.90), it has a relatively a low level of sensitivity 
(0.50)173. This means that some individuals at the extreme right tail of the distribution are 
misclassified as “obese” when they actually carry a relatively large amount of lean body mass. 
The opposite occurs far less often, with individuals at the extreme left tail of the distribution 
almost always being correctly identified as non-obese. However, BMI is used ubiquitously 
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because it is easily measured and has clearly defined clinical thresholds (e.g., underweight, 
morbidly obese) that are robustly associated with mortality and cardiometabolic outcomes173. By 
contrast, the gold standard for measuring body composition, dual energy x ray absorptiometry 
(DEXA), is a lengthy and extremely costly procedure, and its measures of body fat have not been 
translated to clinical thresholds173. 
For a subset of individuals (N = 5,107 European ancestry individuals that were included in our 
GWAS), UKB performed DEXA scans. BMI and impedance measures of body fat were 
available for almost the entire cohort. Below, we compare BMI, DEXA measures of body fat, 
and impedance measures of body fat. 
11.2 Results 
11.2.1 BMI 
The results are reported in Supplementary Table 10.2 and Figure 4. Here, we briefly 
summarize the range of findings for the regression coefficients from the adjusted model. In all 
cohorts, we find that all regression coefficients (for each macronutrient, both in the full and 
adjusted models) are statistically significant at P < 0.001 and always positive for BMI-FAT 
(range: ?̂?𝛽𝑠𝑠𝑠𝑠𝑗𝑗  = [0.051 (UKB), 0.167 (FHS)]) and BMI-PROTEIN (range: 𝛽𝛽 � 𝑠𝑠𝑠𝑠𝑗𝑗  = [0.082 (UKB), 
0.161 (FHS)]) and always negative for BMI-SUGAR (range: ?̂?𝛽𝑠𝑠𝑠𝑠𝑗𝑗 = [-0.111 (FHS), -0.054 
(WHI)]) and BMI-CARBOHYDRATE (range: ?̂?𝛽𝑠𝑠𝑠𝑠𝑗𝑗= [-0.144 (FHS), -0.068 (WHI)]). In the UKB, 
the associations between BMI and CARBOHYDRATE and SUGAR become slightly smaller in 
magnitude after a covariate for physical activity is added, while the associations between BMI 
and FAT and PROTEIN remain virtually unchanged. 
In FHS, HRS and WHI, we are able to distinguish between animal protein versus plant protein; 
added versus natural sugar; and saturated versus unsaturated fat (Supplementary Table 11.2, 
Extended Data Figure 9). The latter distinction is also available in the UKB. We find that 
animal protein has a consistent positive correlation with BMI, with range ?̂?𝛽𝑠𝑠𝑠𝑠𝑗𝑗  = [0.144 (HRS), 
0.177 (FHS)]). Plant protein has a consistent negative correlation with BMI, with range ?̂?𝛽𝑠𝑠𝑠𝑠𝑗𝑗 = [-
0.069 (FHS), -0.059 (HRS)]). The coefficients for saturated and unsaturated fat and natural 
versus added sugar, however, are always in the same direction, with meta-analyzed point 
estimates ?̂?𝛽𝑠𝑠𝑠𝑠𝑗𝑗  = 0.071 for saturated fat, ?̂?𝛽𝑠𝑠𝑠𝑠𝑗𝑗  = 0.028 for unsaturated fat, ?̂?𝛽𝑠𝑠𝑠𝑠𝑗𝑗  = -0.035 for added 
sugar, and ?̂?𝛽𝑠𝑠𝑠𝑠𝑗𝑗  = -0.058 for natural sugar (all P < 0.001). 
These results show that higher relative intake of sugar and carbohydrate is consistently 
associated with lower BMI, while the opposite holds for relative protein and fat intake. For 
PROTEIN, the PROTEIN-BMI association is clearly driven by protein of animal origin.  
For PROTEIN, the estimated coefficient of the phenotypic association with BMI is larger in the 
adjusted model in all four cohorts. Hence, SES appears to partially mask the association between 
relative protein intake and BMI, as PROTEIN is positively correlated with household income and 
negatively correlated with neighborhood deprivation in the UKB (but also negatively correlated 
with educational attainment; Supplementary Table 11.4). Adding covariate for physical activity 
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also and walking pace does not change the association between PROTEIN and BMI in the UKB, 
and the genetic correlation between PROTEIN and physical activity was also positive (yet non-
significant). Hence, it appears that the positive phenotypic association between PROTEIN and BMI 
is not likely the result of confounding by SES or physical activity. 
In the UKB, we also find that BMI is a good proxy measure for total fat mass, especially in 
women, with a higher explained variance in BMI by DEXA-estimate for total fat mass for 
women compared to men (R2 = 0.72 for women vs. R2 = 0.66 for men Supplementary Table 
11.3). BMI is less accurate in detecting body fat percentage and visceral fat mass, however 
(explained variances for body fat percentage: R2 = 0.53 for women and R2 = 0.47 for men; 
visceral fat mass: R2 = 0.49 for women and R2 = 0.53 for men). 
Lastly, we note that BMI does not necessarily have ubiquitous negative health effects across the 
lifespan, as body fat may protect against frailty in elderly populations. This phenomenon is 
known as “the obesity paradox”175,176. Indeed, Levine et al.177 found that the negative metabolic 
health effects of high protein consumption reverse with older age. Hence, it would be premature 
to conclude that (animal) protein consumption leads to poor health based on our findings – not 
only because our findings are correlational but also because of potential age-dependent effects. 
11.2.2 SES 
In Supplementary Table 11.4, we report results of multiple regressions of the four 
macronutrients on the SES indicators: completed years of education, household income, and 
Townsend deprivation index in the UKB. In these regressions, the SES indicators are added 
simultaneously, together with covariates for sex, age, and home location coordinates. In general, 
the associations between the macronutrients and SES were small but significant (largest 
standardized ?̂?𝛽 = -0.103, for CARBOHYDRATE and household income). FAT is the only 
macronutrient that shows a consistent pattern of negative correlations with SES (i.e., negative 
correlation with education, positive correlation with deprivation, and negative correlation with 
income). 
11.2.3 Current drinkers vs. current non-drinkers 
In Supplementary Information 5.2, we speculated that the association between ADH1B and fat 
might be driven by a cross-sectional fat-alcohol substitution effect, where current drinkers 
consume alcohol at the expense of fat compared to non-drinkers. In a sensitivity analysis 
including only non-drinkers, we found that the association between ADH1B and fat disappeared 
(Supplementary Information 5.2), which provided suggestive support for this scenario. In this 
analysis, we used individuals who consumed 0 kilocalories of alcohol according to their dietary 
report. Here, we also explore the possibility that the diets of former drinkers contain a different 
macronutrient composition compared to current or never drinkers. For instance, former drinkers 
may change their dietary composition to compensate for the health effects of past alcohol use, or 
they could attempt to substitute one addictive dietary substance (alcohol) for another (fat).  
To assess these scenarios, we compare the diet composition of current drinkers and current non-
drinkers. We identify these groups on the basis of dietary self-report from the 24HDR data. 
These self-reports of alcohol intake used here are not corrected for the weekday the self-report 
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was for, as we did in Supplementary Information 2.5.2 for the other macronutrients, as this 
could classify non-drinkers as drinkers if their reports were for weekend days. Individuals who 
reported consuming more than 0 kilocalories from alcohol in their 24HDR (dietary report) were 
classified as current drinkers. Individuals who report being former or never drinkers in the 
lifestyle and environment questionnaire (data-field 1558), but who did report consuming more 
than 20 kilocalories from alcohol, were removed from the analyses (N = 264). Individuals who 
identified as current drinkers according to data-field 1558, but who consumed 0 kilocalories from 
alcohol according to their 24HDR report, were also removed (N = 48,761), as were the remainder 
of individuals who did not have 24HDR data at all (N = 260,722). We remove these individuals 
from these analyses because we are interested in comparing former drinkers to the same set of 
individuals that were implicitly classified as “current” drinkers in our GWAS estimation of 
ADH1B’s effects. After excluding individuals, we are left with N = 117,101 confirmed current 
drinkers and N = 4,781 former drinkers. The current drinkers consumed an average of 180 (SD = 
156) kilocalories from alcohol, which corresponds to 8.6% (SD = 7.0) percent of total energy 
intake for these individuals.  
Because the effect size of the macronutrient density difference is easy to interpret, we use 
macronutrient densities in only these analyses. We address the correlation between macronutrient 
densities and total energy intake (Supplementary Information 2.7) by performing linear 
regressions that include a covariate for total energy intake. Since current drinkers might differ 
from non-drinkers with regards to demographic or lifestyle characteristics, we also add 
covariates for sex, birth year, educational attainment, household income, the number of dietary 
self-reports, height, weight, Townsend deprivation index, self-reported total physical activity (as 
defined in Supplementary Information 11.1.3), and walking pace. 
We analyze percentage intake of macronutrients from total and non-alcoholic energy intake. We 
perform multiple regressions of the macronutrients (expressed in % intake from non-alcoholic 
energy) on a binary indicator for former drinking (1 for former drinkers, 0 for “confirmed” 
current drinkers) and the covariates described above.  
The results are summarized in Supplementary Table 11.5. Comparing current and former 
drinkers, we find that former drinkers “swap” calories from alcohol for all other macronutrients, 
but especially for carbohydrates (+ 6.5%, SE = 0.1%) and sugar (+ 3.8%, SE = 0.1%), and less so 
for fat (+ 1.9%, SE = 0.1%) and protein (+ 0.4%, SE = 0.05%). These cross-sectional (i.e., inter-
individual and not within-individual) substitution effects are estimated by including calories 
from alcohol in the total energy equation. However, when we exclude calories from alcohol from 
the total energy equation to make their non-alcoholic energy intakes comparable, we find that 
former drinkers consume relatively less fat (-1.5%, SE = 0.1%) and protein (-0.8%, SE = 0.1%) 
than current drinkers, and more carbohydrates (+ 2.3%, SE = 0.1%) and sugar (+1.9%, SE = 
0.1%). Hence, it appears that former drinkers actually consume less fat and more carbohydrates 
than current drinkers when we focus on non-alcoholic calories. 
We conclude that there are tangible differences in diet composition between former drinkers and 
current drinkers. However, it seems unlikely that an increased “health consciousness” of former 
drinkers drove the ADH1B association with FAT. In this (admittedly somewhat complex) 
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scenario, a subset of individuals with a genetic liability towards alcohol abuse (e.g., because of a 
genetic tendency towards fast alcohol metabolism146) consume relatively less fat after recovery 
from alcohol abuse. Since the GWAS phenotype we create is based on total energy estimates that 
include calories from alcohol, we actually find a discordant effect with respect to alcohol and fat 
intake. That is, the effect allele is associated with decreased alcohol intake is associated with 
increased fat intake. We also find this in our phenotypic association described above: being a 
former drinker is associated with a higher dietary fat percentage when alcohol is included in the 
total energy equation. When we remove alcohol from the total energy equation we do find that 
being a former drinker is associated with a lower dietary fat percentage, but the GWAS 
phenotype was agnostic to this effect.  
We also do not find a significant overall genetic correlation with alcohol abuse and fat intake in 
Supplementary Information 10.3.3. Hence, a more straightforward explanation for the ADH1B 
association remains cross-sectional substitution of alcohol with fat, as a consequence of our 
phenotype construction. This scenario is supported by the fact that we do not find significant 
genetic correlations between diet composition and alcohol dependence. The only question that 
remains is why the ADH1B was only found for fat, when CARBOHYDRATE and SUGAR have much 
stronger phenotypic “substitution” effects for alcohol cross-sectionally. 
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